WO2012032545A1 - Processes for preparing dronedarone and its intermediates - Google Patents
Processes for preparing dronedarone and its intermediates Download PDFInfo
- Publication number
- WO2012032545A1 WO2012032545A1 PCT/IN2011/000614 IN2011000614W WO2012032545A1 WO 2012032545 A1 WO2012032545 A1 WO 2012032545A1 IN 2011000614 W IN2011000614 W IN 2011000614W WO 2012032545 A1 WO2012032545 A1 WO 2012032545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- dronedarone
- butyl
- formula
- hydrochloride
- Prior art date
Links
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 title claims abstract description 156
- 229960002084 dronedarone Drugs 0.000 title claims abstract description 152
- 238000000034 method Methods 0.000 title claims abstract description 113
- 230000008569 process Effects 0.000 title claims abstract description 100
- 239000000543 intermediate Substances 0.000 title abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 113
- 150000003839 salts Chemical class 0.000 claims abstract description 100
- CPKOXUVSOOKUDA-UHFFFAOYSA-N 1-bromo-5-fluoro-2-iodo-4-methylbenzene Chemical compound CC1=CC(I)=C(Br)C=C1F CPKOXUVSOOKUDA-UHFFFAOYSA-N 0.000 claims abstract description 81
- 229960002919 dronedarone hydrochloride Drugs 0.000 claims abstract description 78
- 238000002360 preparation method Methods 0.000 claims abstract description 52
- 239000012535 impurity Substances 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 123
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 111
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 108
- 239000002904 solvent Substances 0.000 claims description 99
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 96
- 238000007792 addition Methods 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 60
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 53
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 47
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 47
- 239000002585 base Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 34
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 32
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 31
- 239000012458 free base Substances 0.000 claims description 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 28
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 24
- SPIIBUQYWNFELT-UHFFFAOYSA-N (5-amino-2-butyl-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(N)C=C12 SPIIBUQYWNFELT-UHFFFAOYSA-N 0.000 claims description 23
- YIYARJKYRBMMJG-UHFFFAOYSA-N 141645-23-0 Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C([N+]([O-])=O)C=C12 YIYARJKYRBMMJG-UHFFFAOYSA-N 0.000 claims description 22
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 22
- 238000002329 infrared spectrum Methods 0.000 claims description 22
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 21
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 18
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 18
- ZJZKLBXEGZKOBW-UHFFFAOYSA-N (2-butyl-5-nitro-1-benzofuran-3-yl)-(4-hydroxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=C([N+]([O-])=O)C=C2C=1C(=O)C1=CC=C(O)C=C1 ZJZKLBXEGZKOBW-UHFFFAOYSA-N 0.000 claims description 17
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 17
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 17
- 239000008096 xylene Substances 0.000 claims description 17
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 16
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 235000006408 oxalic acid Nutrition 0.000 claims description 15
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 14
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14
- 150000007513 acids Chemical class 0.000 claims description 14
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 14
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 14
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 12
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 12
- 150000002576 ketones Chemical class 0.000 claims description 12
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 12
- WYALRXZJYXWYGR-UHFFFAOYSA-N (2-butyl-5-nitro-1-benzofuran-3-yl)-(4-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=C([N+]([O-])=O)C=C2C=1C(=O)C1=CC=C(OC)C=C1 WYALRXZJYXWYGR-UHFFFAOYSA-N 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 11
- DENSIPXSATYPQS-UHFFFAOYSA-N (5-amino-2-butyl-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone;oxalic acid Chemical group OC(=O)C(O)=O.OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(N)C=C12 DENSIPXSATYPQS-UHFFFAOYSA-N 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 10
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 10
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 10
- XGAJABPTUOLUAE-UHFFFAOYSA-N 2-butyl-5-nitro-1-benzofuran Chemical compound [O-][N+](=O)C1=CC=C2OC(CCCC)=CC2=C1 XGAJABPTUOLUAE-UHFFFAOYSA-N 0.000 claims description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 9
- 239000002841 Lewis acid Substances 0.000 claims description 9
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 150000007517 lewis acids Chemical class 0.000 claims description 9
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 9
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 9
- IDLGIQAVACFYMB-UHFFFAOYSA-N (2-butyl-5-nitro-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone;oxalic acid Chemical group OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C([N+]([O-])=O)C=C12 IDLGIQAVACFYMB-UHFFFAOYSA-N 0.000 claims description 8
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 8
- 239000007868 Raney catalyst Substances 0.000 claims description 8
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 8
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 8
- 229940011051 isopropyl acetate Drugs 0.000 claims description 8
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 claims description 8
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 7
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 7
- 150000008282 halocarbons Chemical class 0.000 claims description 7
- 239000011976 maleic acid Substances 0.000 claims description 7
- IKGSSECULYFYER-UHFFFAOYSA-N n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]-n-methylsulfonylmethanesulfonamide Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(N(S(C)(=O)=O)S(C)(=O)=O)C=C12 IKGSSECULYFYER-UHFFFAOYSA-N 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 7
- 229940095064 tartrate Drugs 0.000 claims description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 7
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 6
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 6
- 229940113088 dimethylacetamide Drugs 0.000 claims description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 6
- SBGOGHODWUZHIY-HZPDHXFCSA-N (1r,2r)-n,n'-dimethyl-1,2-bis[3-(trifluoromethyl)phenyl]ethane-1,2-diamine Chemical compound C1([C@@H](NC)[C@H](NC)C=2C=C(C=CC=2)C(F)(F)F)=CC=CC(C(F)(F)F)=C1 SBGOGHODWUZHIY-HZPDHXFCSA-N 0.000 claims description 5
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 5
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 5
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 claims description 5
- 239000012296 anti-solvent Substances 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 229940107700 pyruvic acid Drugs 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 239000001117 sulphuric acid Substances 0.000 claims description 5
- 235000011149 sulphuric acid Nutrition 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 4
- 238000010908 decantation Methods 0.000 claims description 4
- 230000001335 demethylating effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000011968 lewis acid catalyst Substances 0.000 claims description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 claims description 3
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 claims description 3
- 229910003446 platinum oxide Inorganic materials 0.000 claims description 3
- 239000001294 propane Substances 0.000 claims description 3
- 229940090181 propyl acetate Drugs 0.000 claims description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- 229910015900 BF3 Inorganic materials 0.000 claims description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 2
- 229910020275 Na2Sx Inorganic materials 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002598 fumaric acid Drugs 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-N iron;hydrochloride Chemical compound Cl.[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-N 0.000 claims description 2
- 229940098895 maleic acid Drugs 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- PXNGGLZHVYQLFZ-UHFFFAOYSA-N potassium;n,n-diethylethanamine;2-methylpropan-2-olate Chemical compound [K+].CC(C)(C)[O-].CCN(CC)CC PXNGGLZHVYQLFZ-UHFFFAOYSA-N 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000010409 thin film Substances 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000001907 coumarones Chemical class 0.000 abstract description 2
- 239000011541 reaction mixture Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 42
- 229940093499 ethyl acetate Drugs 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 235000011181 potassium carbonates Nutrition 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- -1 bes late Chemical compound 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000013557 residual solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CMQCNTNASCDNGR-UHFFFAOYSA-N toluene;hydrate Chemical compound O.CC1=CC=CC=C1 CMQCNTNASCDNGR-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003891 oxalate salts Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 229940043232 butyl acetate Drugs 0.000 description 2
- HXTLWOZJMYIANK-UHFFFAOYSA-N butyl acetate;methanol Chemical compound OC.CCCCOC(C)=O HXTLWOZJMYIANK-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- ATTUDFIHEIYAFS-UHFFFAOYSA-N 1-benzofuran oxalic acid Chemical group OC(=O)C(O)=O.OC(=O)C(O)=O.C1=CC=C2OC=CC2=C1 ATTUDFIHEIYAFS-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DGZRCNLDVBIYRT-UHFFFAOYSA-N CCCCNc1c(C(c(cc2)ccc2OCCCN)=O)c2cc([N+]([O-])=O)ccc2[o]1 Chemical compound CCCCNc1c(C(c(cc2)ccc2OCCCN)=O)c2cc([N+]([O-])=O)ccc2[o]1 DGZRCNLDVBIYRT-UHFFFAOYSA-N 0.000 description 1
- KJYRVRPXYLDVMY-UHFFFAOYSA-N CCCCc1c(C(c(cc2)ccc2OCCCN)=O)c2cc(N)ccc2[o]1 Chemical compound CCCCc1c(C(c(cc2)ccc2OCCCN)=O)c2cc(N)ccc2[o]1 KJYRVRPXYLDVMY-UHFFFAOYSA-N 0.000 description 1
- XUNGMCIRQHLEEQ-UHFFFAOYSA-O CCCCc1c(C(c(cc2)ccc2OCCC[NH2+]CCCC)=O)c2cc(N)ccc2[o]1 Chemical compound CCCCc1c(C(c(cc2)ccc2OCCC[NH2+]CCCC)=O)c2cc(N)ccc2[o]1 XUNGMCIRQHLEEQ-UHFFFAOYSA-O 0.000 description 1
- KJYRVRPXYLDVMY-UHFFFAOYSA-O CCCCc1c(C(c(cc2)ccc2OCCC[NH3+])=O)c2cc(N)ccc2[o]1 Chemical compound CCCCc1c(C(c(cc2)ccc2OCCC[NH3+])=O)c2cc(N)ccc2[o]1 KJYRVRPXYLDVMY-UHFFFAOYSA-O 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- GZMYLSJUNSCMTD-MOPGFXCFSA-N OC[C@@H](C)NC1=NC(=CC(=C1)C=1C=C(C=CC=1C)NC(=O)N1C[C@@H](CC1)CC(F)(F)F)N1CCOCC1 Chemical compound OC[C@@H](C)NC1=NC(=CC(=C1)C=1C=C(C=CC=1C)NC(=O)N1C[C@@H](CC1)CC(F)(F)F)N1CCOCC1 GZMYLSJUNSCMTD-MOPGFXCFSA-N 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- NJWNEWQMQCGRDO-UHFFFAOYSA-N indium zinc Chemical compound [Zn].[In] NJWNEWQMQCGRDO-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000504 ivabradine hydrochloride Drugs 0.000 description 1
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940032007 methylethyl ketone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940087092 multaq Drugs 0.000 description 1
- AGUODSZYAHKPCT-UHFFFAOYSA-N n-(2-butyl-1-benzofuran-5-yl)-n-methylsulfonylmethanesulfonamide Chemical compound CS(=O)(=O)N(S(C)(=O)=O)C1=CC=C2OC(CCCC)=CC2=C1 AGUODSZYAHKPCT-UHFFFAOYSA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000005243 upper chamber Anatomy 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to dronedarone or its pharmaceutically acceptable acid addition salts. More particularly, it relates to crystalline and amorphous forms of dronedarone or its pharmaceutically acceptable acid addition salts and processes for their preparation. The invention also relates to processes for the preparation of benzofuran derivative and intermediates thereof. The invention also relates to pharmaceutical compositions that includes dronedarone or its pharmaceutically acceptable acid addition salts thereof.
- Dronedarone is a Class III anti-arrhythmia drug for the prevention of cardiac arrhythmias such as atrial fibrillation (AF).
- AF is a condition characterized by an irregular heart beat and occurs when the atria (the upper chambers of the heart) contract very rapidly. This causes the lower chambers of the heart, the ventricles, to contract chaotically so that blood is inefficiently pumped to the body, which can lead to tissue damage and even death.
- 5-benzo- furanyl]methanesulfamide having the Formula (1) is a drug for the treatment of arrhythmia a the US '510).
- the US '510 discloses the method for preparing dronedarone (1), starting from 2-butyl-5-nitrobenzofuran according to the following scheme 1:
- the dronedarone free base was obtained by addition of methane sulfonyl chloride in presence of triethylamine. This results in formation of dimer impurity upto 30%. Therefore, the reaction is not advantageous for industrial scale.
- the dronedarone hydrochloride was prepared by treating dronedarone freebase in anhydrous ethyl acetate using hydrogen chloride in ether. The process is not advantages as its requires dronedarone freebase of high purity to be converted to hydrochloride salt.
- the starting material 2-butyl-5-nitrobenzofuran can be prepared by the processes reported in the US '510 or in J. Methods in Enzymology, 1967, v. 1 1, 556 by H. R. Horton and D. E. oshland or as disclosed in International PCT Publications WO 2001/28974 A2 and WO 2001/29019 Al .
- the US '510 discloses catalytic reduction of 2-butyl-5-nitrobenzofuran (3.4 atm H 2 /Pt0 2 /EtOH) to obtain 2-butyl-5-benzofuranmine free base, which subsequent reaction with methanesulfonlylchloride in the presence of triethylamine as acid scavenger and carbon tetrachloride as a solvent to give N-(2-butyl-5-benzofuranyl)-N- (methylsulfonyl)- methanesulfonamide instead of N-(2-butyl-5- benzofuranyl)methartesulfonarnide.
- Polymorphism is the occurrence of different crystalline forms of a single compound and it is a property of some compounds and complexes. Thus, polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where each form has different and distinct physical properties, such as different solubility profiles, different melting point temperatures and/or different x- ray diffraction peaks. Since the solubility of each polymorph may vary, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predicable solubility profiles. It is desirable to investigate all solid-state forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form.
- polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry.
- X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry.
- EP 2354132 A2 patent application discloses three crystalline forms of dronedarone free base, viz. Form -A, Form-B and Form-C.
- International PCT publications WO 2010/040261 Al and WO 201 1/070380 Al discloses processes for the preparation of dronedarone hydrochloride and intrmediate thereof.
- the European Medicies Agency assessment report for Multaq® discloses it as a white to practically white, non-hygroscopic fine powder. It is practically insoluble in water, sligthly soluble in acetonitrile, soluble in ethanol and freely soluble in methanol, in methylene chloride as well as in dimethylsulfoxide. Only one crystalline form is known and its shows no isomerism. This active substance has no chiral center.
- the inventors have discovered novel pharmaceutically acceptable acid addition salts of dronedarone, particularly in crystalline and amorphous polymorphic forms thereof.
- the inventors have also discovered the crystalline form of dronedarone base and have developed an improved process for the preparation of dronedarone or its pharmaceutically acceptable acid addition salts.
- pharmaceutically acceptable acid additions salts of dronedarone include hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate, and the like in crystalline or amorphous form thereof.
- crystalline Form-A and amorphous form of dronedarone hydrochloride are provided.
- a process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone includes providing a solution of dronedarone in one or more suitable solvents; adding a suitable acid; and isolating the pharmaceutically acceptable acid addition salts of dronedarone by removal of solvents.
- the process includes:
- the process comprises:
- the process comprises: ,
- the process comprises:
- dronedarone of Formula (I) (b) optionally converting dronedarone into one or more of its pharmaceutically acceptable acid addition salts thereof and obtaining dronedarone by treating with suitable base;
- a process for the preparation of amorphous form pharmaceutically acceptable acid addition salts of dronedarone comprising: providing a solution pharmaceutically acceptable acid addition salts of dronedarone in one or more suitable solvents; and isolating the amorphous form pharmaceutically acceptable acid addition salts of dronedarone.
- dronedarone hydrochloride substantially free from disulfonamide impurity.
- Embodiments further include isolated disulfonamide impurity of the following Formula.
- a process for preparing dronedarone hydrochloride or a pharmaceutical composition thereof having less than about 1% by HPLC of N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)- methane sulfonamide (disulfonamide impurity) comprising: measuring level of the dimer impurity in a batch of dronedarone free base, selected a batch having less than about 1% of dimer impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source.
- a process for preparing .dronedarone hydrochloride or a pharmaceutical composition thereof having less than about 1% by HPLC of N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)- methane sulfonamide (disulfonamide impurity) comprising: measuring level of the dimer impurity in a batch of dronedarone free base, selected a batch having less than about 1 % of dimer impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source
- crystalline dronedarone hydrochloride Form-A substantially free from disulfonamide impurity.
- a stable crystalline form of dronedarone hydrochloride thereof which is stable during storage and drying.
- crystalline Form-A of dronedarone hydrochloride having particle size distributions wherein the 10th volume percentile particle size (D10) is less than about 20 ⁇ , the 50th volume percentile particle size (D50) is less than about 50 ⁇ , or the 90th volume percentile particle size (D90) is less than about 100 ⁇ , or any combination thereof.
- a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
- a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride and one or more pharmaceutically acceptable carriers, excipients or diluents.
- FfG. l shows the X-ray diffractogram of crystalline Form-A dronedarone hydrochloride.
- FIG.2 shows the DSC thermogram of crystalline Form-A dronedarone hydrochloride.
- FIG.3 shows the IR spectra of crystalline Form-A dronedarone hydrochloride.
- FIG.4 shows the X-ray diffractogram (XRD) of crystalline dronedarone hydrobromide.
- FIG.5 shows the DSC thermogram of crystalline dronedarone hydrobromide.
- FIG.6 shows the IR spectra of crystalline dronedarone hydrobromide.
- FIG.7 shows the X-ray diffractogram (XRD) of amorphous dronedarone hydrobromide.
- FIG.8 shows the X-ray diffractogram (XRD) of crystalline dronedarone Hydrogensulfate.
- FIG.9 shows the DSC thermogram of crystalline dronedarone hydrogensulfate.
- FIG.10 shows the IR spectra of crystalline dronedarone hydrogensulfate.
- FIG.1 1 shows the X-ray diffractogram (XRD) of amorphous dronedarone hydrogensulfate.
- FIG.12 shows the X-ray diffractogram (XRD) of crystalline dronedarone free base.
- FIG.13 shows the DSC thermogram of crystalline dronedarone free base.
- FIG.14 shows the IR spectra of crystalline dronedarone free base.
- FIG.15 shows the X-ray diffractogram of 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-5-nitro benzofuran oxalate Form-I.
- FIG.16 Shows the differential scanning calorimetry of 2-n-butyl-3-[4-(3-di-n- butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate Form-I.
- FIG.17 Shows the X-ray diffractogram of 5-amino-3-[4-(3-di-n-butylamino-propoXy) benzoyl]-2-n-butyI benzofuran dioxalate Form-I.
- FIG.18 Shows the differential scanning calorimetry of 5-amino-3-[4-(3-di-n- butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate Form-I.
- FIG.19 Shows the X-ray diffractogram of amorphous dronedarone hydrochloride of the present invention.
- the term “substantially free” means dronedarone or its pharmaceutically acceptable acid addition salts thereof having less than 1% of disulfonamide impurity, particularly less than about 0.5% of disulfonamide impurity and most particularly less than about 0.15% of disulfonamide impurity.
- disulfonamide impurity refers to the compound N-(2- butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)methane sulfonamide having the following structure.
- Suitable solvent means a single or a combination of two or more solvents.
- isolation means to the process for removing the solvent comprises one or more of techniques like filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum and the like.
- acid addition salts means hydrobromide, hydrochloride, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like.
- the invention provides pharmaceutically acceptable acid additions salts of dronedarone selected from one or more hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like in crystalline or amorphous form thereof.
- the invention provides crystalline Form-A of dronedarone hydrochloride.
- the crystalline Form-A is characterized by its X-ray powder diffraction pattern, infrared spectrum and differential scanning calorimetry thermogram as shown in Figures 1 , 2, and 3, respectively.
- the inventors also have developed a process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone, the process comprises: providing solution of dronedarone in one or more suitable solvents; addition of suitable acid; and isolating pharmaceutically acceptable acid addition salts of dronedarone by removal of solvents.
- the solution of dronedarone may be obtained by dissolving any known forms of dronedarone free base or dronedarone free base in oil form in a suitable solvent.
- the solution may be obtained by heating the dronedarone in a solvent.
- the suitable acid is added to the resultant solution which may be clarified to remove foreign particulate matter or treated with charcoal to remove coloring and other related impurities.
- the solution so obtained may be concentrated to reduce the amount of solvent.
- the solution may be concentrated by removing the solvent completely to get a residue.
- such a solution may be obtained directly from a reaction in which dronedarone or its pharmaceutically acceptable acid addition salts is formed.
- the solvent may be removed by a technique which includes, for example, filtration, filtration under vacuum, decantation, ce trifugation, distillation and distillation under vacuum.
- the invention provides an improved process for the preparation of dronedarone of Formula (I) or its hydrochloride salt thereof,
- the process comprises:
- the suitable solvents in step (a) comprises of acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, propanol, isobutanol, ethyl acetate, n-butyl acetate, tert-butyl acetate, propyl acetate, toluene, xylene, cyclohexane, n- heptane, acetonitrile and the like.
- methyl ethyl ketone isobutyl ketone, methanol, ethanol, propanol, isobutanol, ethyl acetate, n-butyl acetate, tert-butyl acetate, propyl acetate, toluene, xylene, cyclohexane, n- heptane, acetonitrile and the like.
- Embodiments of the process includes the condensation of 2-n-butyl-3-(4- hydroxybenzoyI)-5-nitrobenzofuran of Formula (V) with l -chloro-3-di-n-butylamino propane is performed in methyl ethyl ketone at an elevated temperature, preferably at 75°C to 85°C in presence of suitable base.
- the suitable base comprises of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide triethylamine, diisopropylamine, n-butylamine, diisopropylethylamine, pyridine, piperidine, ammonia and the like.
- potassium carbonate sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide triethylamine, diisopropylamine, n-butylamine, diisopropylethylamine, pyridine, piperidine, ammonia and the like.
- potassium carbonate potassium carbonate.
- reaction mass may be diluted with water and the separated organic layer may be washed with sodium hydroxide solution to remove unreacted 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) in the form of sodium salt during filtration.
- Further embodiments of the process optionally includes treating compound (IV) with suitable acids comprises of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or into a hydrate thereof.
- suitable acids comprises of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or into a hydrate thereof.
- the acid addition salt of 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-5-nitro benzofuran of Formula (IV A) may be prepared by treating with suitable acid for example oxalic acid in one or more of suitable solvent comprises of methanol, ethanol, isopropanol, ⁇ , ⁇ -dimethylformamide, N,N-dimethyl acetamide, acetone, acetonitrile, THF and water or mixtures thereof.
- suitable acid for example oxalic acid in one or more of suitable solvent comprises of methanol, ethanol, isopropanol, ⁇ , ⁇ -dimethylformamide, N,N-dimethyl acetamide, acetone, acetonitrile, THF and water or mixtures thereof.
- methanol may be used to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate salt.
- the reaction is carried out at an elevated temperature, particularly at about 60°C to 65°C followed by cooling to ambient temperature.
- 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate salt isolated is crystalline characterized by its X-ray powder diffraction pattern, and differential scanning calorimetry thermogram as shown in Figures 15 and 16 respectively.
- the crystalline 2-n-butyl-3-[4-(3-di-n-butylamino- propoxy)-benzoyl]-5-nitro benzofuran oxalate designated as "Form-I” is further characterized by X-ray powder diffraction having peaks at about 5.6, 6.9, 7.3, 13.1, 18.0, 20.5, 23.3, 24.4 and 25.7 ⁇ 0.2° 2 ⁇ or differential scanning calorimetry having endothermic peak 87.85°C and 109.91°C.
- the acid addition salts of Formula (IVA) of 2-n-butyl-3-[4-(3-di-n-butylamino- propoxy)-benzoyl]-5-nitro benzofuran is further treated with suitable base as disclosed herein above to obtain compound of Formula (IV).
- suitable solvent system comprises of toluene-water, toluene-methanol, ethyl acetate-water, butylacetate-methanol and the like.
- toluene-water followed by removal of organic solvent to obtain compound of Formula (IV).
- Embodiments of the process further provides, hydrogenation of compound 2-n- butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran of Formula (IV) in presence of catalyst like Raney Nickel or Palladium.
- catalysts may be replaced by Platinum oxide, Fe-HCl, Sn-HCl, Na 2 Sx and the like.
- the hydrogenation may be conducted in one or more of suitable solvents comprises methanol, ethanol, ethyl acetate, methanol with liquor ammonia, methanol with ammonia gas, ethyl acetate in methanol and the like at about 30 bar pressure in a hydrogenator to obtain 5-amino-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-2-n-butyl benzofuran of Formula (III).
- suitable solvents comprises methanol, ethanol, ethyl acetate, methanol with liquor ammonia, methanol with ammonia gas, ethyl acetate in methanol and the like at about 30 bar pressure in a hydrogenator to obtain 5-amino-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-2-n-butyl benzofuran of Formula (III).
- Further embodiments of the process optionally includes treating compound (III) with suitable acids comprises of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifiuoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or into a hydrate thereof.
- suitable acids comprises of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifiuoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or into a
- the acid addition salt of 5-amino-3-[4-(3-di-n-butylamino-propoxy)- benzoyl] -2-n-buty 1 benzofuran of Formula (IIIA) may be prepared by treating with suitable acid for example oxalic acid in one or more of suitable solvent comprises of methanol, ethanol, isopropanol, N,N-dimethylformamide, ⁇ , ⁇ -dimethyl acetamide, acetone, acetonitrile, THF and water or mixtures thereof.
- suitable acid for example oxalic acid in one or more of suitable solvent comprises of methanol, ethanol, isopropanol, N,N-dimethylformamide, ⁇ , ⁇ -dimethyl acetamide, acetone, acetonitrile, THF and water or mixtures thereof.
- methanol may be used to obtain 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt.
- the reaction is carried out at an elevated temperature, particularly at about 60°C to 65°C followed by cooling to ambient temperature.
- the 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt isolated is crystalline characterized by its X-ray powder diffraction pattern, and differential scanning calorimetry thermogram as shown in Figures 17 and 18 respectively.
- the acid addition salts of Formula (IIIA) of 5-amino-3-[4-(3-di-n-butylamino- propoxy)- benzoyl] -2 -n-butyl benzofuran is further treated with suitable base as disclosed herein above to obtain .compound of Formula (III).
- suitable solvent system comprises of toluene-water, toluene-methanol, ethyl acetate-water, butylacetate-methanol and the like.
- toluene-water followed by removal of organic solvent to obtain compound of Formula (III).
- the compound 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]- 2-n-butyl benzofuran of Formula (III) may be treated with methane sulfonyl chloride in absence of base.
- the reaction proceeds very sluggishly and provides disulfonamide impurity alongwith dronedarone freebase.
- the said reaction is performed in presence of bases like triethylamine, pyridine, diisopropylamine, diisopropylethylamine, DBU or inorganic bases like potassium carbonate, potassium hydroxide, sodium hydroxide.
- bases like triethylamine, pyridine, diisopropylamine, diisopropylethylamine, DBU or inorganic bases like potassium carbonate, potassium hydroxide, sodium hydroxide.
- triethylamine is exemplified.
- the present invention provides the process wherein reaction of
- the compound 5-amino-3-[4-(3-di-n-butylamino- propoxy)benzoyl]-2-n-butyl benzofuran Formula (III) may be treated with methane sulfonyl chloride or methane sulfonic anhydride in absence of base at a temperature of about 50°C to 55°C for atieast about 15-20 hours to obtain dronedarone substantially free from disulfonamide impurity.
- Embodiments of the process further provides converting dronedarone into its hydrochloride salt by treating with hydrochloride source which comprises of dry HC1
- the suitable solvent comprises water, an aromatic hydrocarbon, C ester, C 2 _4 ether, Ci -8 alcohol, acetonitrile and a ketone.
- the suitable solvent comprises methanol, ethanol, isopropanol, butanol, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water or mixtures thereof.
- acetone or ethyl acetate or isopropanol may be used.
- the dronedarone hydrochloride salt may be isolated by addition of isopropanolic hydrochloride in an amount sufficient to provide a pH of about 1 to about
- the invention provides an improved process for the preparation of 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V), an intermediate of dronedarone (V)
- the process comprises:
- the halogenated or non-halogenated solvent comprises wherein the halogenated or non-halogenated hydrocarbons comprises methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, heptane and the like, excluding dichloroethane.
- the lewis acid comprises one or more of aluminum chloride, zinc chloride, boron trifluoride, stannic chloride, titanium tetrachloride, ferric chloride and mixtures thereof, excluding tin tetrachloride.
- Embodiments of the process further includes, demethylating 2-n-butyl-3-(4- methoxybenzoyl) -5-nitrobenzofuran of Formula (VI) in one or, more of suitable solvent.
- suitable solvent comprises of CMO alcohols, C 3-8 ketones, CM esters, halogenated and non-halogenated hydrocarbons, amides, nitriles and the like.
- the suitable solvent comprises of methanol, ethanol, isopropanol, butanol, pentanol, dodecanol, acetone, methyl isobutyl ketone, methyl ethyl ketone, ethyl acetate, tert-butyl acetate, n-butyl acetate, methylene dichloride, chlorobenzene, toluene, xylene, N,N-dimethylformamide, ⁇ , ⁇ -dimethyl- acetamide, acetonitrile, N- methylpyrrolidone, ⁇ , ⁇ -dimethylsulfoxide, sulfolane and the like.
- the reaction may be done at an elevated temperature, particularly at about 65°C to 75°C.
- the reaction mixture may be treated with one or more of suitable solvent comprise of water, alcohols, amide, nitriles, ketones like methanol, ethanol, isopropanol, n-butanol, N,N- dimethylformamide, ⁇ , ⁇ -dimethylacetamide, acetonitrile, acetone, methylisobutyl ketone, methyl ethyl ketone or mixture thereof with water, In particular, water.
- suitable solvent comprise of water, alcohols, amide, nitriles, ketones like methanol, ethanol, isopropanol, n-butanol, N,N- dimethylformamide, ⁇ , ⁇ -dimethylacetamide, acetonitrile, acetone, methylisobutyl ketone, methyl ethyl ketone or mixture thereof with water, In particular, water.
- the process provides extraction of 2-n-butyl-3-(4- hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) in one or more mixture of suitable solvent.
- the suitable solvent comprises of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, n-heptane, n-hexane, ethyl acetate, butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether and the like.
- ethyl acetate is particularly, ethyl acetate.
- the reaction mixture obtained after demethylation may be partitioned between water and ethylacetate at an elevated temperature, particularly at 55°C to 65°C followed by removal of ethyl acetate.
- the residue may be treated with one or more of suitable solvent comprises of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, n-heptane, n-hexane, ethyl acetate, butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether and the like.
- suitable solvent comprises of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, n-heptane, n-hexane, ethyl acetate, butyl acetate, diethyl ether, diisopropyl ether, methyl tert-buty
- the residue obtained is treated with toluene at an elevated temperature, particularly at about 65°C to 75°C for atleast about 60 minutes, particularly for about 30 minutes and may be cooled to ambient temperature.
- an elevated temperature particularly at about 65°C to 75°C for atleast about 60 minutes, particularly for about 30 minutes and may be cooled to ambient temperature.
- at about 5°C to isolate 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V).
- the invention provides an improved process for the preparation of 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA),
- the process comprises:
- the suitable acid addition salts comprises of hydrobromide, hydrochloride, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, bes late, mesylate, tosylate and the like.
- the invention provides a process for the preparation of dronedarone of Formula (I) or its hydrochloride salt thereof;
- the process comprises:
- the suitable solvent comprises of methanol, ethanol, isopropanol, butanol, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water or mixtures thereof.
- the pharmaceutically acceptable acid addition salts comprises salt with hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, . ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid, camphoric acid and the like.
- Embodiments of the process further provides treating pharmaceutically acceptable acid additions salt of dronedarone with suitable base.
- the suitable base comprises of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like.
- potassium carbonate or sodium hydroxide is particularly preferred.
- Embodiments of the process further provides converting dronedarone into its hydrochloride salt by treating with hydrochloride source which comprises of dry HC1 (g), isopropanolic HCl, Aqueous HCl, Cone. HCl, Ethyl Acetate-HCl and the like in one or more of suitable solvent.
- hydrochloride source which comprises of dry HC1 (g), isopropanolic HCl, Aqueous HCl, Cone. HCl, Ethyl Acetate-HCl and the like in one or more of suitable solvent.
- the suitable solvent comprises water, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, methanol, ethanol, isopropanol, butanol, dodecanol, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water or mixtures thereof.
- the invention provides dronedarone of Formula (I) or its pharmaceutically acceptable acid addition salts substantially free from disulfonamide impurity.
- dronedarone hydrochloride substantially free from disulfonamide impurity.
- crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
- the crystalline Form-A of dronedarone hydrochloride may be characterized by
- the invention provides an isolated N-(2-butyl-3-(4-(3- (dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methane sulfonamide "disulfonamide impurity" of following structure.
- the invention provides a process for preparing dronedarone hydrochloride or a pharmaceutical composition thereof having less than about 1% of N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)- methane sulfonamide (disulfonamide impurity) determined by HPLC; comprising: measuring level of the disulfonamide impurity in a batch of dronedarone free base, selected a batch having less than about 1% of disulfonamide impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source.
- Another aspect of the invention provides crystalline Form-A of dronedarone hydrochloride having particle size distributions wherein the 10th volume percentile particle size (D10) is less than about 20 ⁇ , the 50th volume percentile particle size (D50) is less than about 50 ⁇ , or the 90th volume percentile particle size (D90) is less than about 100 ⁇ , or any combination thereof.
- a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
- a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride and one or more pharmaceutically acceptable carriers, excipients or diluents.
- the invention provides a pharmaceutically acceptable acid addition salts of dronedarone selected from one or more of hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like.
- a pharmaceutically acceptable acid addition salts of dronedarone selected from one or more of hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like.
- Embodiments also include formation of crystalline and amorphous forms of pharmaceutically acceptable acid addition salts of dronedarone.
- pharmaceutically acceptable acid addition salts of dronedarone characterized by:
- Crystalline dronedarone hydrobromide characterized by atleast one of the following: (a) X-ray powder diffraction having characteristic peaks at about 7.6°, 8.0°, 13.0, 13.5, 15.4, 16.1, 20.1, 20.6, 22.2, 22.9, 23.7 and 25.8 ⁇ 0.2° (2 ⁇ ) or X-ray powder diffraction substantially as depicted in FIG.4; or
- the invention provides pharmaceutically acceptable acid additions salts of dronedarone in amorphous form.
- the amorphous form of may be characterized by:
- the pharmaceutically acceptable acid addition salts like crystalline dronedarone hydrobromide or crystalline dronedarone hydrogensuifate may have particle size distributions the 10 th volume percentile particle size (D ] 0 ) is less than about 50 ⁇ , the 50th volume percentile particle size (D 50 ) is less than about 250 urn, or the 90 volume percentile particle size (D 90 ) is less than about 500 ⁇ , or any combination thereof.
- the invention provides a process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone, the process comprises: (a) providing solution of dronedarone in one or more suitable solvents;
- the suitable solvent comprises one or more of C1-C4 alcohols, ketones, esters, aprotic solvents, water and the like or mixture thereof.
- the suitable solvent comprises of methanol, ethanol, isopropanol, n-butanol, heptanol, decanol, dodecanol, acetone, methyl ethyl ketone, methyl tert-butyl ketone, ethyl acetate, isopropyl acetate, butyl acetate, n-propyl acetate, dimethyl formamide, dimethyl acetamide, N-methylpyrrolidone, acetonitrile and water or mixture thereof.
- the suitable acid comprises of hydrobromic acid, sulfuric acid, hydrochloric acid, phosphoric acid, oxalic acid, tartartic acid, succinic acid, maleic acid, fumaric acid, benzenesulfonic acid, methanesulfonic acid, toluenesulfonic acid and the like.
- Embodiments of the process further includes removal of the solvent comprises one or more of filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum.
- the process may further include optionally addition of one or more of suitable anti-solvent comprises of toluene, xylene, ethylbenzene, n-hexane, heptane, cyclohexane, and the like; ethers like diisopropylether, methyltert-butyl ether, tetrahydrofuran, and the like; In particular, hexane.
- suitable anti-solvent comprises of toluene, xylene, ethylbenzene, n-hexane, heptane, cyclohexane, and the like; ethers like diisopropylether, methyltert-butyl ether, tetrahydrofuran, and the like; In particular, hexane.
- the invention provides a process for the preparation of amorphous form pharmaceutically acceptable acid addition salt of dronedarone, the process comprising: providing a solution pharmaceutically acceptable acid addition salts of dronedarone in one or more suitable solvent; and isolating the amorphous form pharmaceutically acceptable acid addition salt of dronedarone.
- Embodiments of the process includes, providing a solution of pharmaceutically acceptable acid addition salts of dronedarone in one or more suitable solvent or mixture of solvent.
- the said solution may be obtained by: (i) direct use of a reaction mixture containing pharmaceutically acceptable acid addition salt of dronedarone that is obtained in the course of its synthesis; or
- the suitable solvent comprises of water; alcohols such as methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, 1-pentanol, 2-pentanol, amyl alcohol, ethylene glycol, glycerol and the like; ketones such as acetone, butanone, 2- pentanone, 3-pentanone, methyl butyl ketone, methyl isobutyi ketone, and the like; esters such as ethyl formate, methyl acetate, ethyl acetate, propyl acetate, t-butyl acetate, isobutyi acetate, hydrocarbons like toluene, xylene, methylene dichloride, ethylene dichloride, chlorobenzene, and the like, nitriles like acetonitrile, and polar aprotic solvents like N,N-dimethyIformamide, N,
- the isolation of an amorphous form of pharmaceutically acceptable acid addition salt of dronedarone from the said solution may be affected by removing solvent.
- Suitable techniques which may be used for the removal of solvent include using a rotational distillation device such as a Buchi Rotavapor, spray drying, agitated thin film dyring ("ATFD”), freeze drying (lyophilization), and the like or any other suitable technique.
- the invention provides spray drying a solution of pharmaceutically acceptable acid addition salt of dronedarone and that involves the spray drying of feed stock, which is prepared as hereinafter, wherein any crystalline form of pharmaceutically acceptable acid addition salt of dronedarone may be used.
- the feedstock is dozed into the spray-drying instrument JISL Mini Spray-drier LSD-48 and spray drying is carried out under the following parameters.
- dronedarone or the filtered cake that is obtained as an end result of the reaction or reaction mass comprising pharmaceutically acceptable acid addition salts of dronedarone or solution comprising pharmaceutically acceptable acid addition salts of dronedarone can be used for the preparation of feed stock.
- the present invention provides compositions comprising dronedarone hydrochloride substantially free of one or more of its corresponding impurities as measured by HPLC.
- compositions comprising dronedarone hydrochloride substantially free residual solvents as measured by GC.
- compositions comprising dronedarone hydrochloride substantially free from crystalline forms.
- Amorphous dronedarone hydrochloride is characterized as substantially depicted in XRD (FIG.19).
- the invention provides a process for the preparation of crystalline dronedarone free base, the process comprising:
- the suitable solvent comprises of Q-C4 alcohols like methanol, ethanol, isopropanol, n-butanol, heptanol, decanol, dodecanol, ketones like acetone, methyl ethyl ketone, methyl tert-butyl ketone and the like, esters like ethyl acetate, isopropyl acetate, butyl acetate, n-propyl acetate and the like, aromatic hydrocarbons like toluene, xylene, ethylbenzene, and the like.
- toluene may be used as a solvent.
- the suitable base comprises of sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, or ammonia and the like.
- the base can be potassium carbonate. More particularly, the potassium carbonate may be added as solution in water or dry solid powder.
- the suitable anti-solvent comprises of aliphatic hydrocarbons like n-heptane, n- hexane, cyclohexane and the like, ethers like diethyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran and the like.
- n-hexane aliphatic hydrocarbons like n-heptane, n- hexane, cyclohexane and the like
- ethers like diethyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran and the like.
- n-hexane aliphatic hydrocarbons like n-heptane, n- hexane, cyclohexane and the like
- ethers like diethyl ether, diisopropyl ether, methyl tert-butyl
- Embodiments of the process includes, suspending dronedarone hydrochloride prepared by the process of the present invention in an aromatic hydrocarbon solvent to provide solution optionally by heating the suspension and aqueous potassium carbonate solution may be added and reaction mixture may be further heated.
- the reaction mixture may be heated from about 35°C to about 90°C.
- the organic layer may be separated followed by washing with water and may be subjected to distillation to remove organic solvent.
- the residue obtained may be treated with suitable antisolvent like hexane.
- the slurry may be cooled prior to filtration to isolate dronedarone free base.
- the crystalline dronedarone free base may be characterized by X-ray powder diffraction having characteristic peaks at about 2.6°, 5.3°, 8.0°, 10.8°, 17.8°, 18.9°, 19.7°, 22.4° and 23.6° ⁇ 0.2° (2 ⁇ ); IR spectra having characteristic peaks at 3182, 2954, 2927, 1625, 1600, 1556, 1508, 1469, 1373, 1328, 1253, 1 143, 979, 912, 846, 798, 783, 756, and 648 cm “ ' ; and DSC thermogram having two endothermic peaks at about 55.68°C and 67.47°C.
- the crystalline dronedarone free base may be characterized by a PXRD pattern substantially as depicted in FIG.12, IR spectra is substantially as depicted in FIG.13 and DSC thermogram is substantially as depicted in FIG.14.
- a stable crystalline form of dronedarone hydrochloride thereof which is stable during storage and drying.
- the present invention provides crystalline Form-A of dronedarone hydrochloride having an chemical purity of greater than about 95%, or greater than about 98%, or greater than about 99%, or greater than about 99.5%, or greater than about 99.8%, or greater than about 99.9%, as determined using high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- Powder X-ray Diffraction of dronedarone hydrochloride form can be obtained under following conditions.
- the X-ray powder diffraction spectrum was measured under the following experimental conditions: Instrument : X-Ray Diffractometer, D/Max-2200/PC Make: Rigaku, Japan.
- compositions comprising dronedarone hydrochloride or salts thereof of the invention.
- pharmaceutical compositions or “pharmaceutical Formulations” includes tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.
- compositions containing the dronedarone hydrochloride of the invention may be prepared by using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, surface active agents, and lubricants.
- diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, surface active agents, and lubricants.
- modes of administration of the pharmaceutical compositions of the invention can be selected depending on the therapeutic purpose, for example tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations. 2011/000614
- An embodiment of the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of crystalline dronedarone hydrochloride substantially free from amorphous form, and one or more pharmaceutically acceptable carriers, excipients or diluents.
- the residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added.
- the reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C.
- the product was filtered and washed with methanol and dried to obtain 2-n-butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5- nitro benzofuran oxalate salt. Purity > 99.5% (HPLC).
- the oxalate salt is characterized by XRD substantially as depicted in FIG.15 and DSC substantially as depicted in FIG.16.
- step (A) The oxalate salt obtained in step (A) was converted to 2-n-butyl-3-[4-(3-di-n- butylamino-propoxy)benzoyl]-5-nitro benzofuran free base by treatment with potassium carbonate in biphasic solvent system toluene and water. The residue was isolated by removal of solvent by distillation under vacuum. Purity > 99.5% (HPLC).
- Example-4 -
- the dioxalate salt is characterized by XRD substantially as depicted in FIG.17 and DSC substantially as depicted in FIG.18
- the reaction mixture was flushed with nitrogen pressure two times and filtered under nitrogen atmosphere at 25°C followed by washing with 50 mL methanol.
- the filtrate was distilled under vacuum at 65°C to obtain residue.
- the residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added.
- the reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C.
- the product was filtered and washed with methanol and dried to obtain 5-amino 3-[4-(3-di-n- butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt.
- the dioxalate salt is characterized by XRD substantially as depicted in FIG.17 and DSC substantially as depicted in FIG.18
- the process can also be conveniently completed by using dry methanolic ammonia solution prepared by using ammonia gas in methanol.
- the dioxalate salt can be converted to free base as per the process described in method- 1.
- the reaction mixture was flushed with nitrogen pressure two times and filtered under nitrogen atmosphere at 25°C followed by washing with 50 mL methanol.
- the filtrate was distilled under vacuum at 65°C to obtain residue.
- the residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added.
- the reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C.
- the product was filtered and washed with methanol and dried to obtain 5-amino 3-[4- (3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt. Purity > 98% (HPLC).
- the dioxalate salt is characterized by XRD substantially as depicted in FIG.17 and DSC substantially as depicted in FIG.18
- the dioxalate salt can be converted to freebase as per the process described in method- 1.
- the separated organic layer was charcoalized with 2.5 g activated charcoal at 60°C and filtered through hyflow bed and washed with 100 mL toluene at 60°C.
- the organic layer was distilled under vacuum to obtain 95% 2-n-butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]5-methyl-sulfonamido benzofuran (dronedarone) as an oil. Purity > 99.5% (HPLC).
- the spray-dried Dronedarone hydrochloride is amorphous in nature.
- the obtained product contains residual solvent well within ICH limit.
- the spray-dried dronedarone hydrobromide is amorphous in nature.
- the obtained product contains residual solvent well within ICH limit.
- the amorphous form is characterized by XRD substantially as depicted in FIG.7.
- 10.0 g of crystalline dronedarone hydrogensulfate is dissolved in 250.0 mL of ethyl acetate at 25°C to 30°C. The content is stirred for 30 minutes at 25°C to 30°C. To this, 1.0 g charcoal was added and stirred for 30 minutes at 25°C to 30°C. The content is filtered through Hyflosupercel, and the Hyflosupercel pad is washed with 50.0 mL ethyl acetate. The filtrate is concentrated under vacuum below 45°C till 100 mL acetone remains. 50 mL ethyl acetate was added and stirred to get clear solution. The solution was spray dried in JISL Mini spray drier LSD-48 under the below conditions. The product is collected from cyclone and is further dried at 40°C ⁇ 5°C under vacuum for 16 hours to get 7.5 g of amorphous dronedarone hydrogensulfate.
- the spray-dried Dronedarone hydrobromide is amorphous in nature.
- the obtained product contains residual solvent well within ICH limit.
- the amorphous form is characterized by XRD substantially as depicted in FIG. l 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to process for the preparation of benzofuran derivative and intermediates thereof. More particularly, it relates to processes for the preparation of dronedarone or pharmaceutically acceptable acid addition salts thereof in crystalline form. The invention also relates to pharmaceutical compositions that include the dronedarone hydrochloride in crystalline form substantially free from disulfonamide impurity.
Description
PROCESSES FOR PREPARING DRONEDARONE AND ITS INTERMEDIATES
FIELD OF THE INVENTION
The invention relates to dronedarone or its pharmaceutically acceptable acid addition salts. More particularly, it relates to crystalline and amorphous forms of dronedarone or its pharmaceutically acceptable acid addition salts and processes for their preparation. The invention also relates to processes for the preparation of benzofuran derivative and intermediates thereof. The invention also relates to pharmaceutical compositions that includes dronedarone or its pharmaceutically acceptable acid addition salts thereof.
BACKGROUND OF THE INVENTION
The following discussion of the prior art is intended to present the invention in an appropriate technical context and allow its significance to be properly appreciated.
Unless clearly indicated to the contrary, however, reference to any prior art in this specification should be construed as an admission that such art is widely known or forms part of common general knowledge in the field.
Dronedarone is a Class III anti-arrhythmia drug for the prevention of cardiac arrhythmias such as atrial fibrillation (AF). AF is a condition characterized by an irregular heart beat and occurs when the atria (the upper chambers of the heart) contract very rapidly. This causes the lower chambers of the heart, the ventricles, to contract chaotically so that blood is inefficiently pumped to the body, which can lead to tissue damage and even death.
Dronedarone, SR 33589, N-[2-Butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-
5-benzo- furanyl]methanesulfamide having the Formula (1), is a drug for the treatment of arrhythmia a the US '510).
(D
The US '510 discloses the method for preparing dronedarone (1), starting from 2-butyl-5-nitrobenzofuran according to the following scheme 1:
l
Methane sulfonyl chloride
The above chemical pathway has following drawbacks:
(a) friedel craft reaction of anisoyl chloride with 2-butyl-5-nitrobenzofuran in presence of tin tetrachloride involves use of class-I solvent ethylene dichloride. Also, tin tetrachloride is costly reagent and can be easily be replaced with suitable lewis acid.
(b) friedel craft reaction of anisoyl chloride with 2-butyl-5-nitrobenzofuran in presence of tin tetrachloride involves stirring for 24 hours i.e. longer duration of reaction.
(c) demethylation of methyl protecting group with aluminum chloride is also reported in ethylene dichloride, which is class 1 solvent.
(d) the reduction of 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5-nitro benzofuran is disclosed with usage of platinum oxide in ethanol. It is very costly reagent for reduction.
(e) 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5-nitro benzofuran is reported as oxalate salt with melting point 84°C (ether/isopropanol). There is no method for its preparation provided.
(f) the dronedarone free base was obtained by addition of methane sulfonyl chloride in presence of triethylamine. This results in formation of dimer impurity upto 30%. Therefore, the reaction is not advantageous for industrial scale.
(g) the dronedarone hydrochloride was prepared by treating dronedarone freebase in anhydrous ethyl acetate using hydrogen chloride in ether. The process is not advantages as its requires dronedarone freebase of high purity to be converted to hydrochloride salt.
(h) further, the melting point of dronedarone hydrochloride is reported at 143°C (acetone). There is no method for its recrystallization provided.
The starting material 2-butyl-5-nitrobenzofuran can be prepared by the processes reported in the US '510 or in J. Methods in Enzymology, 1967, v. 1 1, 556 by H. R. Horton and D. E. oshland or as disclosed in International PCT Publications WO 2001/28974 A2 and WO 2001/29019 Al .
The US '510 discloses catalytic reduction of 2-butyl-5-nitrobenzofuran (3.4 atm H2/Pt02/EtOH) to obtain 2-butyl-5-benzofuranmine free base, which subsequent reaction with methanesulfonlylchloride in the presence of triethylamine as acid scavenger and carbon tetrachloride as a solvent to give N-(2-butyl-5-benzofuranyl)-N- (methylsulfonyl)- methanesulfonamide instead of N-(2-butyl-5- benzofuranyl)methartesulfonarnide.
Polymorphism is the occurrence of different crystalline forms of a single compound and it is a property of some compounds and complexes. Thus, polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where each form has different and distinct physical properties, such as different solubility profiles, different melting point temperatures and/or different x- ray diffraction peaks. Since the solubility of each polymorph may vary, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predicable solubility profiles. It is desirable to investigate all solid-state forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. The polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry. For a general review of polymorphs and the pharmaceutical applications of polymorphs, See G. M. Wall, Pharm Manuf. 3, 33 (1986); K. Haleblian and W. McCrone, J. Pharm. Sci., 58, 911 (1969); and J. K. Haleblian, J. Pharm. Sci., 64, 1269 (1975), all of which are incorporated herein by reference.
EP 2354132 A2 patent application discloses three crystalline forms of dronedarone free base, viz. Form -A, Form-B and Form-C. International PCT publications WO 2010/040261 Al and WO 201 1/070380 Al discloses processes for the preparation of dronedarone hydrochloride and intrmediate thereof.
Several processes for the preparation of dronedarone hydrochloride and intermediates thereof is reported in of ivabradine hydrochloride and their processes for preparation have been disclosed, for example in U.S. Patent Nos 7,312,345 B2, 6,828,448 B2, 6,846,936 B2, 6,984,741 B2, 6,855,842 B l and U.S. Patent application No. 201 1/0009649 Al .
The European Medicies Agency assessment report for Multaq® (dronedarone hydrochloride) discloses it as a white to practically white, non-hygroscopic fine powder. It is practically insoluble in water, sligthly soluble in acetonitrile, soluble in ethanol and freely soluble in methanol, in methylene chloride as well as in dimethylsulfoxide. Only one crystalline form is known and its shows no isomerism. This active substance has no chiral center.
In view of the above, it is therefore, desirable to provide an efficeint more economical, less hazardous and eco-friendly process for the preparation of dronedarone or its pharmaceutically acceptable salts thereof in crystalline form or amorphous form. The crystalline forms disclosed herein is atleast stable under oridinary stability conditions with respect to purity, storage and is free flowing powder and substantailly free from amorphous form. The process is simple, cost-effective, eco-friendly and commercially viable.
SUMMARY OF THE INVENTION
The inventors have discovered novel pharmaceutically acceptable acid addition salts of dronedarone, particularly in crystalline and amorphous polymorphic forms thereof. The inventors have also discovered the crystalline form of dronedarone base and have developed an improved process for the preparation of dronedarone or its pharmaceutically acceptable acid addition salts.
In one general aspect, there are provided pharmaceutically acceptable acid additions salts of dronedarone. The pharmaceutically acceptable acid additions salts include hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate, and the like in crystalline or amorphous form thereof.
In another general aspect there are provided crystalline Form-A and amorphous form of dronedarone hydrochloride.
In another general aspect there is provided a process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone. The process includes providing a solution of dronedarone in one or more suitable solvents; adding a suitable acid; and isolating the pharmaceutically acceptable acid addition salts of dronedarone by removal of solvents.
In another general aspect, there is provided an improved process for the preparation of dronedarone of Formula (I) or its hydrochloride salt.
(I)
The process includes:
(a) reacting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) with 1- chloro-3-di-n-butylamino propane in one or more suitable solvents in the presence of a suitable base to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5- nitro benzofuran of Formula (IV);
(IV)
(b) optionally, isolating 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzo- furan acid addition salt of Formula (IV A) by reacting with one or more suitable acids and liberating the compound of Formula (IV) by treating with a suitable base;
. Acid Addition Salt
(IVA)
(c) hydrogenating the compound of Formula (IV) in presence of Raney Nickel or Palladium catalyst to obtain 5-amino 3-[4-(3-di-n-butyiamino-propoxy)benzoyl]-2- n-butyl benzofuran of Formula (III);
(III)
(d) optionally, preparing 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA) by reacting with one or more of suitable acids and obtaining compound of Formula (III) by treating with suitable base;
. Acid Addition Salt
(IIIA)
(e) reacting compound of Formula (III) with methanesulfonyl chloride or methanesulfonic anhydride in absence of base in one or more of suitable solvents to obtain dronedarone; and
(f) optionally, converting dronedarone to its hydrochloride salt thereof by treating with a hydrochloric acid source.
In another general aspect, there is provided an improved process for the preparation of 2^n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V), an intermediate of dronedarone
(V)
the process comprises:
(a) reacting 2-n-butyl-5-nitrobenzofuran with anisoyi chloride in the presence of a , Lewis acid in one or more of halogenated or non-halogenated hydrocarbon solvent to obtain 2-n-Butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran of Formula (VI); with proviso that Lewis acid is not tin tetrachloride and halogenated hydrocarbon is not dichloroethane,
(VI)
(b) demethylating 2-n-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran of Formula (VI) in presence of lewis acid catalyst in one or more of suitable solvents;
(c) extracting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) in one or more mixture of suitable solvents followed by removal of suitable solvent;
(d) treating residue with one or more of suitable solvents; and
(e) isolating 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V).
In another general aspect, there is provided an improved process for the preparation of 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA),
. Acid Addition Salt
(IIIA)
the process comprises: ,
(a) reacting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) with 1 - chloro-3-di-n-butylamino propane in one or more of suitable solvents in presence of suitable base to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5- nitro benzofuran of F
(IV)
(b) optionally, isolating 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzo- furan acid addition salt of Formula (IV A) by reacting with one or more of suitable acids and liberating compound of Formula (IV) by treating with suitable base;
. Acid Addition Salt
(IVA)
(c) hydrogenating the compound of Formula (IV) with Raney Nickel or 10% Palladium on carbon to obtain 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III); and
(HI)
(d) isolating 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA) by reacting with one or more of suitable acids. In further general aspect, there is provided a process for the preparation of dronedarone of Formula (I) or its hydrochloride salt thereof;
(I)
the process comprises:
(III)
with methane sulfonyl chloride or methane sulfonic anhydride in absence of one or more of suitable solvents to obtain dronedarone of Formula (I);
(b) optionally converting dronedarone into one or more of its pharmaceutically acceptable acid addition salts thereof and obtaining dronedarone by treating with suitable base; and
(c) converting dronedarone to its hydrochloride salt thereof by treating with a hydrochloric acid source.
In another general aspect, there is provided a process for preparing dronedarone hydrochloride comprising:
(a) combining dronedarone and one or more of suitable solvent selected from the group consisting of water, a hydrocarbon, ester, C2^ ether, Ci-8 alcohol, acetonitrile, ketone and the like;
(b) adding hydrochloric acid in an amount sufficient to dronedarone hydrochloride; and
(c) isolating dronedarone hydrochloride.
In further general aspect there is provided a process for the preparation of amorphous form pharmaceutically acceptable acid addition salts of dronedarone, the process comprising: providing a solution pharmaceutically acceptable acid addition salts of dronedarone in one or more suitable solvents; and isolating the amorphous form pharmaceutically acceptable acid addition salts of dronedarone.
According to one of the general aspect, there is provided dronedarone hydrochloride substantially free from disulfonamide impurity. Embodiments further include isolated disulfonamide impurity of the following Formula.
According to another general aspect, there are provided Crystalline 5-amino-3- [4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate Form-I characterized by X-ray powder diffraction as depicted in FIG.15 and differential scanning caiorimetry as depicted in FIG.16 as well as Crystalline 2-n-butyl-3-[4-(3-di- n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate Form-I characterized by X-ray powder diffraction as depicted in FIG. 17 and differential scanning caiorimetry as depicted in FIG.18.
In another general aspect, there is provided a process for preparing dronedarone hydrochloride or a pharmaceutical composition thereof having less than about 1% by HPLC of N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)- methane sulfonamide (disulfonamide impurity) comprising: measuring level of the dimer impurity in a batch of dronedarone free base, selected a batch having less than about 1% of dimer impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source.
In another general aspect, there is provided a process for preparing .dronedarone hydrochloride or a pharmaceutical composition thereof having less than about 1% by HPLC of N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)- methane sulfonamide (disulfonamide impurity) comprising: measuring level of the dimer impurity in a batch of dronedarone free base, selected a batch having less than about 1 % of dimer impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source
In another general aspect, there is provided crystalline dronedarone hydrochloride Form-A substantially free from disulfonamide impurity.
In another general aspect, there is provided a stable crystalline form of dronedarone hydrochloride thereof, which is stable during storage and drying.
In another general aspect, there is provided crystalline Form-A of dronedarone hydrochloride having particle size distributions wherein the 10th volume percentile particle size (D10) is less than about 20 μιη, the 50th volume percentile particle size (D50) is less than about 50 μηι, or the 90th volume percentile particle size (D90) is less than about 100 μηι, or any combination thereof.
In another general aspect, there is provided a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
In another general aspect, there is provided a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride and one or more pharmaceutically acceptable carriers, excipients or diluents.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
FfG. l shows the X-ray diffractogram of crystalline Form-A dronedarone hydrochloride.
FIG.2 shows the DSC thermogram of crystalline Form-A dronedarone hydrochloride. FIG.3 shows the IR spectra of crystalline Form-A dronedarone hydrochloride.
FIG.4 shows the X-ray diffractogram (XRD) of crystalline dronedarone hydrobromide. FIG.5 shows the DSC thermogram of crystalline dronedarone hydrobromide.
FIG.6 shows the IR spectra of crystalline dronedarone hydrobromide.
FIG.7 shows the X-ray diffractogram (XRD) of amorphous dronedarone hydrobromide. FIG.8 shows the X-ray diffractogram (XRD) of crystalline dronedarone Hydrogensulfate.
FIG.9 shows the DSC thermogram of crystalline dronedarone hydrogensulfate.
FIG.10 shows the IR spectra of crystalline dronedarone hydrogensulfate.
FIG.1 1 shows the X-ray diffractogram (XRD) of amorphous dronedarone hydrogensulfate.
FIG.12 shows the X-ray diffractogram (XRD) of crystalline dronedarone free base.
FIG.13 shows the DSC thermogram of crystalline dronedarone free base.
FIG.14 shows the IR spectra of crystalline dronedarone free base.
FIG.15 shows the X-ray diffractogram of 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-5-nitro benzofuran oxalate Form-I.
FIG.16 Shows the differential scanning calorimetry of 2-n-butyl-3-[4-(3-di-n- butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate Form-I.
FIG.17 Shows the X-ray diffractogram of 5-amino-3-[4-(3-di-n-butylamino-propoXy) benzoyl]-2-n-butyI benzofuran dioxalate Form-I.
FIG.18 Shows the differential scanning calorimetry of 5-amino-3-[4-(3-di-n- butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate Form-I.
FIG.19 Shows the X-ray diffractogram of amorphous dronedarone hydrochloride of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
As used herein the term "substantially free" means dronedarone or its pharmaceutically acceptable acid addition salts thereof having less than 1% of disulfonamide impurity, particularly less than about 0.5% of disulfonamide impurity and most particularly less than about 0.15% of disulfonamide impurity.
The term "disulfonamide impurity" as used herein refers to the compound N-(2- butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)methane sulfonamide having the following structure.
All ranges recited herein include the endpoints, including those that recite a range "between" two values. Terms such as "about", "general", "substantially," and the like are to be construed as modifying a term or value such that it is not an absolute. Such terms will be defined by the circumstances and the terms that they modify as those terms are understood by those skill in the art. This includes, at very least, the degree of expected experimental error, technique error and instrument error for a given technique used to measure a value.
"Suitable solvent" means a single or a combination of two or more solvents.
The term "isolation" used herein means to the process for removing the solvent comprises one or more of techniques like filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum and the like.
The term "acid addition salts" used herein means hydrobromide, hydrochloride, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like.
In one aspect, the invention provides pharmaceutically acceptable acid additions salts of dronedarone selected from one or more hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like in crystalline or amorphous form thereof.
In another general aspect, the invention provides crystalline Form-A of dronedarone hydrochloride. The crystalline Form-A is characterized by its X-ray powder diffraction pattern, infrared spectrum and differential scanning calorimetry thermogram as shown in Figures 1 , 2, and 3, respectively.
The inventors also have developed a process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone, the process comprises: providing solution of dronedarone in one or more suitable solvents; addition of suitable
acid; and isolating pharmaceutically acceptable acid addition salts of dronedarone by removal of solvents.
In general, the solution of dronedarone may be obtained by dissolving any known forms of dronedarone free base or dronedarone free base in oil form in a suitable solvent. The solution may be obtained by heating the dronedarone in a solvent. The suitable acid is added to the resultant solution which may be clarified to remove foreign particulate matter or treated with charcoal to remove coloring and other related impurities. The solution so obtained may be concentrated to reduce the amount of solvent. The solution may be concentrated by removing the solvent completely to get a residue.
Alternatively, such a solution may be obtained directly from a reaction in which dronedarone or its pharmaceutically acceptable acid addition salts is formed. The solvent may be removed by a technique which includes, for example, filtration, filtration under vacuum, decantation, ce trifugation, distillation and distillation under vacuum. '
In another aspect, the invention provides an improved process for the preparation of dronedarone of Formula (I) or its hydrochloride salt thereof,
(I)
the process comprises:
(a) reacting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) with 1- chloro-3-di-n-butylamino propane in one or more of suitable solvent in presence of suitable base to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5- nitro benzofuran of F
(b) optionally, isolating 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzo- furan acid addition salt of Formula (IV A) by reacting with one or more of suitable acids and liberating compound of Formula (IV) by treating with suitable base;
. Acid Addition Salt
(IVA)
(c) hydrogenating the compound of Formula (IV) in presence of Raney Nickel or Palladium catalyst to obtain 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2- n-butyl benzofuran of Formula (III);
(HI)
(d) optionally, preparing 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (ΙΠΑ) by reacting with one or more of suitable acids and obtaining compound of Formula (III) by treating with suitable base;
. Acid Addition Salt
(HIA)
(e) reacting compound of Formula (III) with methanesulfonyl chloride or methanesulfonic anhydride in absence of base in one or more of suitable solvents to obtain dronedarone; and
(f) optionally, converting dronedarone to its hydrochloride salt thereof by treating with a hydrochloric acid source.
In general, the suitable solvents in step (a) comprises of acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, propanol, isobutanol, ethyl acetate, n-butyl acetate, tert-butyl acetate, propyl acetate, toluene, xylene, cyclohexane, n- heptane, acetonitrile and the like. In particular, methyl ethyl ketone.
Embodiments of the process includes the condensation of 2-n-butyl-3-(4- hydroxybenzoyI)-5-nitrobenzofuran of Formula (V) with l -chloro-3-di-n-butylamino propane is performed in methyl ethyl ketone at an elevated temperature, preferably at 75°C to 85°C in presence of suitable base.
The suitable base comprises of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide triethylamine, diisopropylamine, n-butylamine, diisopropylethylamine, pyridine, piperidine, ammonia and the like. In particular, potassium carbonate.
In general, after the completion of the reaction the reaction mass may be diluted with water and the separated organic layer may be washed with sodium hydroxide solution to remove unreacted 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) in the form of sodium salt during filtration.
Further embodiments of the process optionally includes treating compound (IV) with suitable acids comprises of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or into a hydrate thereof. In particular, oxalic acid. The salt may be further treating with suitable base to obtain compound (IV).
In general, the acid addition salt of 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-5-nitro benzofuran of Formula (IV A) may be prepared by treating with suitable acid for example oxalic acid in one or more of suitable solvent comprises of methanol, ethanol, isopropanol, Ν,Ν-dimethylformamide, N,N-dimethyl acetamide, acetone, acetonitrile, THF and water or mixtures thereof. In particular, methanol may be used to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate salt. The reaction is carried out at an elevated temperature, particularly at about 60°C to 65°C followed by cooling to ambient temperature.
In general, the 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate salt isolated is crystalline characterized by its X-ray powder diffraction pattern, and differential scanning calorimetry thermogram as shown in Figures 15 and 16 respectively. The crystalline 2-n-butyl-3-[4-(3-di-n-butylamino- propoxy)-benzoyl]-5-nitro benzofuran oxalate designated as "Form-I" is further
characterized by X-ray powder diffraction having peaks at about 5.6, 6.9, 7.3, 13.1, 18.0, 20.5, 23.3, 24.4 and 25.7±0.2° 2Θ or differential scanning calorimetry having endothermic peak 87.85°C and 109.91°C.
The acid addition salts of Formula (IVA) of 2-n-butyl-3-[4-(3-di-n-butylamino- propoxy)-benzoyl]-5-nitro benzofuran is further treated with suitable base as disclosed herein above to obtain compound of Formula (IV). The reaction may be carried out in one or more of suitable solvent system comprises of toluene-water, toluene-methanol, ethyl acetate-water, butylacetate-methanol and the like. In particular, toluene-water followed by removal of organic solvent to obtain compound of Formula (IV).
Embodiments of the process further provides, hydrogenation of compound 2-n- butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran of Formula (IV) in presence of catalyst like Raney Nickel or Palladium. In general, the said catalysts may be replaced by Platinum oxide, Fe-HCl, Sn-HCl, Na2Sx and the like. The hydrogenation may be conducted in one or more of suitable solvents comprises methanol, ethanol, ethyl acetate, methanol with liquor ammonia, methanol with ammonia gas, ethyl acetate in methanol and the like at about 30 bar pressure in a hydrogenator to obtain 5-amino-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-2-n-butyl benzofuran of Formula (III).
Further embodiments of the process optionally includes treating compound (III) with suitable acids comprises of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifiuoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or into a hydrate thereof. In particular, oxalic acid. The salt may be further treating with suitable base to obtain compound (IIIA).
In general, the acid addition salt of 5-amino-3-[4-(3-di-n-butylamino-propoxy)- benzoyl] -2-n-buty 1 benzofuran of Formula (IIIA) may be prepared by treating with suitable acid for example oxalic acid in one or more of suitable solvent comprises of methanol, ethanol, isopropanol, N,N-dimethylformamide, Ν,Ν-dimethyl acetamide, acetone, acetonitrile, THF and water or mixtures thereof. In particular, methanol may be used to obtain 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt. The reaction is carried out at an elevated temperature, particularly at about 60°C to 65°C followed by cooling to ambient temperature.
In general, the 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt isolated is crystalline characterized by its X-ray powder diffraction pattern, and differential scanning calorimetry thermogram as shown in Figures 17 and 18 respectively. The crystalline 5-amino-3-[4-(3-di-n-butylamino- propoxy)benzoyl]-2-n-butyl benzofuran dioxalate Form-I characterized by X-ray powder diffraction having peaks at about 7.5, 10.0, 10.7, 15.3, 17.6, 20.1, 22.5, 24.6, 27.9 and 30.1±0.2° 2Θ or differential scanning calorimetry having endothermic peak at about 173.76°C.
The acid addition salts of Formula (IIIA) of 5-amino-3-[4-(3-di-n-butylamino- propoxy)- benzoyl] -2 -n-butyl benzofuran is further treated with suitable base as disclosed herein above to obtain .compound of Formula (III). The reaction may be carried out in one or more of suitable solvent system comprises of toluene-water, toluene-methanol, ethyl acetate-water, butylacetate-methanol and the like. In particular, toluene-water followed by removal of organic solvent to obtain compound of Formula (III).
In general, the compound 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]- 2-n-butyl benzofuran of Formula (III) may be treated with methane sulfonyl chloride in absence of base.
The inventors of the present invention have found that sulfonation of 5-amino- 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III) performed as per the process disclosed in U.S. Patent No. 5,223,510 in presence of triethylamine (base) provides about 25-30% of N-(2-butyl-3-(4-(3- (dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methane
The reaction proceeds very sluggishly and provides disulfonamide impurity alongwith dronedarone freebase. The said reaction is performed in presence of bases like triethylamine, pyridine, diisopropylamine, diisopropylethylamine, DBU or
inorganic bases like potassium carbonate, potassium hydroxide, sodium hydroxide. In particular, triethylamine is exemplified.
In general aspect, the present invention provides the process wherein reaction of
5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-h-butyl benzofuran Formula (III) is treated with methane sulfonyl chloride or methane sulfonic anhydride in absence of base. The reaction may be carried out at an elevated temperature at about 75°C to
120°C, particularly at about 100°C to 1 10°C for atieast about 2 hours to selectively provide dronedarone substantially free from disulfonamide impurity.
In another general aspect, the compound 5-amino-3-[4-(3-di-n-butylamino- propoxy)benzoyl]-2-n-butyl benzofuran Formula (III) may be treated with methane sulfonyl chloride or methane sulfonic anhydride in absence of base at a temperature of about 50°C to 55°C for atieast about 15-20 hours to obtain dronedarone substantially free from disulfonamide impurity.
Embodiments of the process further provides converting dronedarone into its hydrochloride salt by treating with hydrochloride source which comprises of dry HC1
(g), isopropanolic HC1, Aqueous HC1, Cone. HC1, Ethyl Acetate-HCl and the like in one or more of suitable solvent.
In general, the suitable solvent comprises water, an aromatic hydrocarbon, C ester, C2_4 ether, Ci-8 alcohol, acetonitrile and a ketone. Particularly, the suitable solvent comprises methanol, ethanol, isopropanol, butanol, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water or mixtures thereof. In particular, acetone or ethyl acetate or isopropanol may be used.
In general, the dronedarone hydrochloride salt may be isolated by addition of isopropanolic hydrochloride in an amount sufficient to provide a pH of about 1 to about
5 to obtain dronedarone hydrochloride.
In another general aspect, the invention provides an improved process for the preparation of 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V), an intermediate of dronedarone
(V)
the process comprises:
(a) reacting 2-n-butyl-5-nitrobenzofuran with anisoyi chloride in the presence of a lewis acid in one or more of halogenated or non-halogenated hydrocarbon solvent to obtain 2-n-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran of Formula (VI); with proviso that lewis acid is not tin tetrachloride and halogenated hydrocarbon is not dichloroethane,
(VI)
(b) demethylating 2-n-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran of Formula (VI) in presence of lewis acid catalyst in one or more of suitable solvents;
(c) extracting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) in one or more mixture of suitable solvent followed by removal of suitable solvent;
(d) treating residue with one or more of suitable solvents; and
(e) isolating 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V).
In general, the halogenated or non-halogenated solvent comprises wherein the halogenated or non-halogenated hydrocarbons comprises methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, heptane and the like, excluding dichloroethane.
The lewis acid comprises one or more of aluminum chloride, zinc chloride, boron trifluoride, stannic chloride, titanium tetrachloride, ferric chloride and mixtures thereof, excluding tin tetrachloride.
Embodiments of the process further includes, demethylating 2-n-butyl-3-(4- methoxybenzoyl) -5-nitrobenzofuran of Formula (VI) in one or, more of suitable solvent. The suitable solvent comprises of CMO alcohols, C3-8 ketones, CM esters, halogenated and non-halogenated hydrocarbons, amides, nitriles and the like. In particular, the suitable solvent comprises of methanol, ethanol, isopropanol, butanol, pentanol, dodecanol, acetone, methyl isobutyl ketone, methyl ethyl ketone, ethyl acetate, tert-butyl acetate, n-butyl acetate, methylene dichloride, chlorobenzene, toluene, xylene, N,N-dimethylformamide, Ν,Ν-dimethyl- acetamide, acetonitrile, N- methylpyrrolidone, Ν,Ν-dimethylsulfoxide, sulfolane and the like.
In general, the reaction may be done at an elevated temperature, particularly at about 65°C to 75°C. After the demethylation is completed, the reaction mixture may be treated with one or more of suitable solvent comprise of water, alcohols, amide, nitriles, ketones like methanol, ethanol, isopropanol, n-butanol, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, acetone, methylisobutyl ketone, methyl ethyl ketone or mixture thereof with water, In particular, water.
Further general aspect of the process provides extraction of 2-n-butyl-3-(4- hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) in one or more mixture of suitable solvent. The suitable solvent comprises of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, n-heptane, n-hexane, ethyl acetate, butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether and the like. In particular, ethyl acetate.
Embodiments of the process provides, the reaction mixture obtained after demethylation may be partitioned between water and ethylacetate at an elevated temperature, particularly at 55°C to 65°C followed by removal of ethyl acetate. The residue may be treated with one or more of suitable solvent comprises of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, n-heptane, n-hexane, ethyl acetate, butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether and the like. In particular, toluene.
In general, the residue obtained is treated with toluene at an elevated temperature, particularly at about 65°C to 75°C for atleast about 60 minutes, particularly for about 30 minutes and may be cooled to ambient temperature. In particular at about 5°C to isolate 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V).
In another general aspect, the invention provides an improved process for the preparation of 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA),
. Acid Addition Salt
(IIIA)
the process comprises:
(a) reacting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) with 1- chloro-3-di-n-butylamino propane in one or more of suitable solvents in presence of
suitable base to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5- nitro benzofuran of Fo
(IV)
(b) optionally, isolating 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzo- furan acid addition salt of Formula (IVA) by reacting with one or more of suitable acids and liberating compound of Formula (IV) by treating with suitable base;
. Acid Addition Salt
(IVA)
(c) hydrogenating the compound of Formula (IV) with Raney Nickel or 10% Palladium on carbon to obtain 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III); and
(III)
(d) isolating 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA) by reacting with one or more of suitable acids.
In general, the suitable acid addition salts comprises of hydrobromide, hydrochloride, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, bes late, mesylate, tosylate and the like.
In further general aspect, the invention provides a process for the preparation of dronedarone of Formula (I) or its hydrochloride salt thereof;
the process comprises:
(a) reacting 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III)
with methane sulfonyl chloride or methane sulfonic anhydride in absence of base in one or more of suitable solvents to obtain dronedarone of Formula (I);
(b) optionally converting dronedarone into one or more of its pharmaceutically acceptable acid addition salts thereof and obtaining dronedarone by treating with suitable base; and
(c) converting dronedarone to its hydrochloride salt thereof by treating with a hydrochloric acid source.
In general, the suitable solvent comprises of methanol, ethanol, isopropanol, butanol, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water or mixtures thereof. In particular, acetone or ethyl acetate or isopropanol.
In general, the pharmaceutically acceptable acid addition salts comprises salt with hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, . ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid, camphoric acid and the like.
Embodiments of the process further provides treating pharmaceutically acceptable acid additions salt of dronedarone with suitable base. The suitable base comprises of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like. In particular, potassium carbonate or sodium hydroxide.
Embodiments of the process further provides converting dronedarone into its hydrochloride salt by treating with hydrochloride source which comprises of dry HC1
(g), isopropanolic HCl, Aqueous HCl, Cone. HCl, Ethyl Acetate-HCl and the like in one or more of suitable solvent.
In another general aspect, there is provided a process for preparing dronedarone hydrochloride comprising:
(a) combining dronedarone and one or more of suitable solvent selected from the group consisting of water, a hydrocarbon, C ester, C2-4 ether, Ci-8 alcohol, acetonitrile, ketone and the like;
(b) adding hydrochloric acid in an amount sufficient to form dronedarone hydrochloride; and
(c) isolating dronedarone hydrochloride.
In general, the suitable solvent comprises water, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, methanol, ethanol, isopropanol, butanol, dodecanol, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water or mixtures thereof.
In another general aspect, the invention provides dronedarone of Formula (I) or its pharmaceutically acceptable acid addition salts substantially free from disulfonamide impurity. In particular, dronedarone hydrochloride substantially free from disulfonamide impurity. More particularly, crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
In general, the crystalline Form-A of dronedarone hydrochloride may be characterized by
(a) X-ray powder diffraction having peaks at about 7.6, 8.0, 1 1.8, 13.7, 15.6, 19.9, 21.5, 23.4, 23.8, 26.0 and 26.8±0.2° 2Θ or X-ray powder diffraction substantially as depicted in FIG.1; or
(b) Fourier Transform Infrared spectra having peaks at about 3060, 2872, 2488, 1637, 1602, 1570, 1462, 1373, 1255, 1 155, 977, 810, 777, 667 and 505 cm"1 or Fourier Transfer Infrared spectra substantially as depicted in FIG.2; or
(c) Differential scanning calorimetry having endothermic peak at about 145.54°C or differential scanning calorimetry substantially as depicted in FIG.3.
In one general aspect, the invention provides an isolated N-(2-butyl-3-(4-(3- (dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methane sulfonamide "disulfonamide impurity" of following structure.
In another general aspect, the invention provides a process for preparing dronedarone hydrochloride or a pharmaceutical composition thereof having less than about 1% of N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)- methane sulfonamide (disulfonamide impurity) determined by HPLC; comprising: measuring level of the disulfonamide impurity in a batch of dronedarone free base, selected a batch having less than about 1% of disulfonamide impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source.
Another aspect of the invention provides crystalline Form-A of dronedarone hydrochloride having particle size distributions wherein the 10th volume percentile particle size (D10) is less than about 20 μηι, the 50th volume percentile particle size (D50) is less than about 50 μπι, or the 90th volume percentile particle size (D90) is less than about 100 μηι, or any combination thereof.
In another general aspect, there is provided a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
In another general aspect, there is provided a pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride and one or more pharmaceutically acceptable carriers, excipients or diluents.
In another general aspect, the invention provides a pharmaceutically acceptable acid addition salts of dronedarone selected from one or more of hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate and the like. Embodiments also include formation of crystalline and amorphous forms of pharmaceutically acceptable acid addition salts of dronedarone. In one general aspect, there is provided pharmaceutically acceptable acid addition salts of dronedarone characterized by:
(i) Crystalline dronedarone hydrobromide characterized by atleast one of the following:
(a) X-ray powder diffraction having characteristic peaks at about 7.6°, 8.0°, 13.0, 13.5, 15.4, 16.1, 20.1, 20.6, 22.2, 22.9, 23.7 and 25.8±0.2° (2Θ) or X-ray powder diffraction substantially as depicted in FIG.4; or
(b) IR spectra having characteristic peaks at 3984, 2872, 2686, 2600, 1638, 1602, 1572, 1257, 1 157, 1048, 975, 777, 656, and 509 cm"1 or Fourier Transfer Infrared spectra substantially as depicted in FIG.5; or
(c) DSC having endothermic peak at about 134.97°C or differential scanning calorimetry substantially as depicted in FIG.6.
(ii) Crystalline dronedarone hydrogensuifate characterized by atleast one of the following:
(a) X-ray powder diffraction having characteristic peaks at about 4.7°, 10. , 18.0°, 20.0°, 22.0°, 23.6° and 25.5°±0.2° (2Θ) or X-ray powder diffraction substantially as depicted in FIG.8; or
(b) IR spectra having characteristic peaks at 2960, 2933, 2872, 1735, 161 1, 1598, 1571, 1508, 1465, 1371 , 1253, 1 157, 1 1 16, 1020, 929, 904 815, 777, and 522 cm'1 or
Fourier Transfer Infrared spectra substantially as depicted in FIG.9; or
(c) DSC having endothermic peak at about 1 14.97°C or differential scanning calorimetry substantially as depicted in FIG.10. According to another general aspect, the invention provides pharmaceutically acceptable acid additions salts of dronedarone in amorphous form. The amorphous form of may be characterized by:
(i) amorphous dronedarone hydrobromide characterized by X-ray powder diffraction substantially as depicted in FIG.7.
(ii) amorphous dronedarone hydrogensuifate characterized by X-ray powder diffraction substantially as depicted in FIG.11.
(iii) amorphous dronedarone hydrochloride characterized by X-ray powder diffraction substantially as depicted in FIG.19.
In general, the pharmaceutically acceptable acid addition salts like crystalline dronedarone hydrobromide or crystalline dronedarone hydrogensuifate may have particle size distributions the 10th volume percentile particle size (D] 0) is less than about 50 μτη, the 50th volume percentile particle size (D50) is less than about 250 urn, or the
90 volume percentile particle size (D90) is less than about 500 μηι, or any combination thereof.
In another general aspect, the invention provides a process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone, the process comprises: (a) providing solution of dronedarone in one or more suitable solvents;
(b) adding suitable acid; and
(c) isolating pharmaceutically acceptable acid addition salt of dronedarone by removal of solvents.
In general, the suitable solvent comprises one or more of C1-C4 alcohols, ketones, esters, aprotic solvents, water and the like or mixture thereof. In particular, the suitable solvent comprises of methanol, ethanol, isopropanol, n-butanol, heptanol, decanol, dodecanol, acetone, methyl ethyl ketone, methyl tert-butyl ketone, ethyl acetate, isopropyl acetate, butyl acetate, n-propyl acetate, dimethyl formamide, dimethyl acetamide, N-methylpyrrolidone, acetonitrile and water or mixture thereof.
In general, the suitable acid comprises of hydrobromic acid, sulfuric acid, hydrochloric acid, phosphoric acid, oxalic acid, tartartic acid, succinic acid, maleic acid, fumaric acid, benzenesulfonic acid, methanesulfonic acid, toluenesulfonic acid and the like.
Embodiments of the process further includes removal of the solvent comprises one or more of filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum.
In general, the process may further include optionally addition of one or more of suitable anti-solvent comprises of toluene, xylene, ethylbenzene, n-hexane, heptane, cyclohexane, and the like; ethers like diisopropylether, methyltert-butyl ether, tetrahydrofuran, and the like; In particular, hexane.
In another general aspect, there is provided a process for the preparation of amorphous form of dronedarone hydrochloride thereof without simultaneous formation of crystalline forms or which will enable the conversion of crystalline forms into the amorphous from.
In further general aspect, the invention provides a process for the preparation of amorphous form pharmaceutically acceptable acid addition salt of dronedarone, the process comprising: providing a solution pharmaceutically acceptable acid addition
salts of dronedarone in one or more suitable solvent; and isolating the amorphous form pharmaceutically acceptable acid addition salt of dronedarone.
Embodiments of the process includes, providing a solution of pharmaceutically acceptable acid addition salts of dronedarone in one or more suitable solvent or mixture of solvent. The said solution may be obtained by: (i) direct use of a reaction mixture containing pharmaceutically acceptable acid addition salt of dronedarone that is obtained in the course of its synthesis; or
(ii) dissolving pharmaceutically acceptable acid addition salt of dronedarone in one or more of suitable solvent.
The suitable solvent comprises of water; alcohols such as methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, 1-pentanol, 2-pentanol, amyl alcohol, ethylene glycol, glycerol and the like; ketones such as acetone, butanone, 2- pentanone, 3-pentanone, methyl butyl ketone, methyl isobutyi ketone, and the like; esters such as ethyl formate, methyl acetate, ethyl acetate, propyl acetate, t-butyl acetate, isobutyi acetate, hydrocarbons like toluene, xylene, methylene dichloride, ethylene dichloride, chlorobenzene, and the like, nitriles like acetonitrile, and polar aprotic solvents like N,N-dimethyIformamide, N,N-dimethylacetamide, N- methylpyrrolidone, pyridine, dimethylsulfoxide, sulfolane, formamide, acetamide, propanamide, pyridine and the like; and mixtures thereof.
In general, the isolation of an amorphous form of pharmaceutically acceptable acid addition salt of dronedarone from the said solution may be affected by removing solvent. Suitable techniques which may be used for the removal of solvent include using a rotational distillation device such as a Buchi Rotavapor, spray drying, agitated thin film dyring ("ATFD"), freeze drying (lyophilization), and the like or any other suitable technique.
In one general aspect, the invention provides spray drying a solution of pharmaceutically acceptable acid addition salt of dronedarone and that involves the spray drying of feed stock, which is prepared as hereinafter, wherein any crystalline form of pharmaceutically acceptable acid addition salt of dronedarone may be used. The feedstock is dozed into the spray-drying instrument JISL Mini Spray-drier LSD-48 and spray drying is carried out under the following parameters.
Sr. No Parameters Conditions
00614
dronedarone or the filtered cake that is obtained as an end result of the reaction or reaction mass comprising pharmaceutically acceptable acid addition salts of dronedarone or solution comprising pharmaceutically acceptable acid addition salts of dronedarone, can be used for the preparation of feed stock.
In one general aspect, the present invention provides compositions comprising dronedarone hydrochloride substantially free of one or more of its corresponding impurities as measured by HPLC.
An aspect of the present invention provides compositions comprising dronedarone hydrochloride substantially free residual solvents as measured by GC.
An aspect of the present invention provides compositions comprising dronedarone hydrochloride substantially free from crystalline forms.
Amorphous dronedarone hydrochloride is characterized as substantially depicted in XRD (FIG.19).
In another aspect, the invention provides a process for the preparation of crystalline dronedarone free base, the process comprising:
(a) providing suspension of dronedarone hydrochloride in one or more of suitable solvent;
(b) adding suitable base;
(c) extracting the aqueous layer with one or more of suitable solvents;
(d) removal of solvent to obtain residue;
(e) adding one or more suitable anti-solvent; and
(f) isolating crystalline dronedarone free base.
In general, the suitable solvent comprises of Q-C4 alcohols like methanol, ethanol, isopropanol, n-butanol, heptanol, decanol, dodecanol, ketones like acetone, methyl ethyl ketone, methyl tert-butyl ketone and the like, esters like ethyl acetate, isopropyl
acetate, butyl acetate, n-propyl acetate and the like, aromatic hydrocarbons like toluene, xylene, ethylbenzene, and the like. In particular, toluene may be used as a solvent.
The suitable base comprises of sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, or ammonia and the like. In particular, the base can be potassium carbonate. More particularly, the potassium carbonate may be added as solution in water or dry solid powder.
The suitable anti-solvent comprises of aliphatic hydrocarbons like n-heptane, n- hexane, cyclohexane and the like, ethers like diethyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran and the like. In particular, n-hexane.
Embodiments of the process includes, suspending dronedarone hydrochloride prepared by the process of the present invention in an aromatic hydrocarbon solvent to provide solution optionally by heating the suspension and aqueous potassium carbonate solution may be added and reaction mixture may be further heated. The reaction mixture may be heated from about 35°C to about 90°C. The organic layer may be separated followed by washing with water and may be subjected to distillation to remove organic solvent. The residue obtained may be treated with suitable antisolvent like hexane. In general, prior to the initiation of product crystallization or the slurry may be cooled prior to filtration to isolate dronedarone free base.
In general; the crystalline dronedarone free base may be characterized by X-ray powder diffraction having characteristic peaks at about 2.6°, 5.3°, 8.0°, 10.8°, 17.8°, 18.9°, 19.7°, 22.4° and 23.6°±0.2° (2Θ); IR spectra having characteristic peaks at 3182, 2954, 2927, 1625, 1600, 1556, 1508, 1469, 1373, 1328, 1253, 1 143, 979, 912, 846, 798, 783, 756, and 648 cm"' ; and DSC thermogram having two endothermic peaks at about 55.68°C and 67.47°C.
The crystalline dronedarone free base may be characterized by a PXRD pattern substantially as depicted in FIG.12, IR spectra is substantially as depicted in FIG.13 and DSC thermogram is substantially as depicted in FIG.14.
In one another aspect, there is provided a stable crystalline form of dronedarone hydrochloride thereof, which is stable during storage and drying.
In an aspect, the present invention provides crystalline Form-A of dronedarone hydrochloride having an chemical purity of greater than about 95%, or greater than about 98%, or greater than about 99%, or greater than about 99.5%, or greater than
about 99.8%, or greater than about 99.9%, as determined using high performance liquid chromatography (HPLC).
According to further embodiment, the scope of the present invention can be illustrated by scheme- 1 as shown below.
(i) Base
(III)
(II)
(i) Base
(ii) Methane sulfoi
Dronedarone Hydrochloride
Scheme-1
Powder X-ray Diffraction of dronedarone hydrochloride form can be obtained under following conditions.
(i) Characterization by Powder X-ray Diffraction
The X-ray powder diffraction spectrum was measured under the following experimental conditions:
Instrument : X-Ray Diffractometer, D/Max-2200/PC Make: Rigaku, Japan.
X- Ray : Cu/40kv/40mA
Diverging : 10
Scattering Slit : 10
Receiving Slit : 0.15 mm
Monochromator RS : 0.8 mm
Counter : Scintillation Counter
Scan Mode : Continuous
Scan Speed : 3.0000 / Min
Sampling Width : 0.020
Scan Axes : Two Theta / Theta
Scan Range : 2.0000 to 40.0000
Theta Offset : 0.0000
(ii) Characterization by Differential Scanning Calorimetry (DSC)
Analytical method: Differential scanning calorimetric analysis was performed using a Perkin Elmer Diamond DSC control unit and a DSC 300°C differential scanning calorimeter. 2-5 mg samples were placed in crimped aluminum pans and heated from 50°C to 250°C in a liquid nitrogen atmosphere at a heating rate of 10°C/minute. Zinc- Indium was used as the standard substance.
(iii) The IR spectrum was measured by the KBr method.
The invention also encompasses pharmaceutical compositions comprising dronedarone hydrochloride or salts thereof of the invention. As used herein, the term "pharmaceutical compositions" or "pharmaceutical Formulations" includes tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.
Pharmaceutical compositions containing the dronedarone hydrochloride of the invention may be prepared by using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, surface active agents, and lubricants. Various modes of administration of the pharmaceutical compositions of the invention can be selected depending on the therapeutic purpose, for example tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.
2011/000614
An embodiment of the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of crystalline dronedarone hydrochloride substantially free from amorphous form, and one or more pharmaceutically acceptable carriers, excipients or diluents.
Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification.
Example-1:
Preparation of 2-n-butyl 3-(4-methoxy benzoyl)-5-nitro benzofuran
Method-1:
44.5 g 2-n-butyl-5-nitro benzofuran and 44.3 g of anisoyl chloride in 310 ml of dichloromethane were taken in round bottom flask at 25°C. The reaction mixture was treated with 44.3 g of ferric chloride solution in 300 ml methylene dichloride. The reaction medium was heated under reflux for 2 hours, cooled and diluted with 40 ml of water. The organic phase was separated and washed with water, 5% sodium hydrogen carbonate solution. The organic phase was evaporated to dryness and the product thus obtained crystallizes rapidly. It was recrystallized from 250 ml of isopropanol and 90% of 2-n-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran.
M.P.: 94-96°C, Purity > 95% (HPLC).
Method-2:
45 g (0.2 mole) 2-ri-butyl 5-nitro benzofuran and 44 g of anisoyl chloride in 300 ml of chlorobenzene were taken in round bottom flask at 25°C. The reaction mixture was treated with 40 g of aluminum chloride solution in 300. ml chlorobenzene. The reaction medium was heated under reflux for 2 hours, cooled and diluted with 40 ml of water. The organic phase was separated and washed with water, 5% sodium hydrogen carbonate solution. The organic phase was evaporated to dryness and the product thus obtained crystallizes rapidly. It was recrystallized from 270 ml of isopropanol and 90% of 2-n-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran.
M.P.: 94-96°C, Purity > 96% (HPLC)
Example-2:
Preparation of 2-n-butyl 3-(4-hydroxy benzovD-5-nitro benzofuran
100 g 2-n-butyl-3-(4-methoxy benzoyl)-5-nitro benzofuran, 500 mL of chlorobenzene, and 143.40 g of aluminum chloride were heated at 75°C for 2 hours to
obtain solution-A. 1 L water was cooled to 5°C and solution-A was added to it. The reaction mixture was heated to 65°C and stirred for 30 min. The organic layer was separated and washed with water at 65°C. The organic layer was distilled under vacuum at 80°C. The residue was treated with 400 mL ethyl acetate at 60°C and cooled to 10°C gradually. In another round bottom flask 500 mL water was cooled to 10°C and above reaction mixture was quenched in pre-cooled water. The reaction mixture was stirred for 30 min and settled at 25°C. The organic layer was separated and washed with 300 mL of water. The ethyl acetate layer was distilled under vacuum at 55°C. The residue was treated with 200 mL toluene and heated to 75°C for 30 min. The reaction mixture was allowed to cool. The precipitated product was filtered and washed with toluene. The product was dried in hot air oven for about 8 hours at 60°C to 65°C to obtain 92% 2-n-butyl-3-(4-hydroxy benzoyl)-5-nitro benzofuran.
M.P. 120°C, Purity (HPLC): 99.19%
Example-3:
Preparation of 2-n-butyl 3-f4-(3-di-n-burylamino-propoxy)benzoyll-5-nitro benzofuran
(A) 2-n-butyl 3-f4-(3-di-n-butylamino-propoxy)benzoyl1-5-nitro benzofuran oxalate salt
100 g 2-n-butyl-3-(4-hydroxy benzoyl)-5-nitro-benzofuran, 800 mL methyl ethyl ketone and 42.80 g of potassium carbonate were stirred at 25°C for 15 min. 63.70 g of l-chloro-3-di-n-butylamino propane was added to the reaction mixture and heated at 85°C for 20 hours. The reaction mixture was filtered and washed with 100 mL of methyl ethyl ketone. The filtrate was diluted with 500 mL water and stirred for 30 min.
The organic layer was separated, treated with 300 mL sodium hydroxide (5%) solution and allowed to settle. The separated organic layer was washed with water, distilled under vacuum and cooled 25°C to obtain 95% 2-n-butyl-3-[4-(3-di-n-butylamino- propoxy)benzoyl]-5-nitro benzofuran. Purity: > 95% (HPLC).
The residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added. The reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C. The product was filtered and washed with methanol and dried to obtain 2-n-butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5- nitro benzofuran oxalate salt. Purity > 99.5% (HPLC).
The oxalate salt is characterized by XRD substantially as depicted in FIG.15 and DSC substantially as depicted in FIG.16.
(B) 2-n-butyl 3-f4-f3-di-n-butvIamino-propoxy)benzoyIl-5-nitro benzofuran
The oxalate salt obtained in step (A) was converted to 2-n-butyl-3-[4-(3-di-n- butylamino-propoxy)benzoyl]-5-nitro benzofuran free base by treatment with potassium carbonate in biphasic solvent system toluene and water. The residue was isolated by removal of solvent by distillation under vacuum. Purity > 99.5% (HPLC). Example-4: -
Preparation of 5-amino 3-f4-(3-di-n-butylamino-propoxy)benzoyll-2-n-butyl benzofuran
Method-l:
(A) 5-amino 3-f4-(3-di-n-butylamino-propoxy)benzoyll-2-n-butyl benzofuran dioxalate salt
100 g 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5-nitro benzofuran, 700 mL methanol and 15 g of Raney Nickel were taken under nitrogen atmosphere at 25°C in 2.0 L autoclave. Hydrogen pressure of 0.5-1.0 Kg was flushed two times and released at 25°C. The hydrogen pressure upto 3.0 Kg/cm2 was applied and the reaction mixture was heated to 55°C. Further the pressure was increased to 5.0 Kg/cm2 and maintained for 8 hours at 55°C. After the completion of the reaction as monitored by TLC, the reaction mixture was cooled to 25°C. The reaction mixture was flushed with nitrogen pressure two times and filtered under nitrogen atmosphere at 25°C followed by washing with 50 mL methanol. The filtrate was distilled under vacuum at 65°C to obtain residue. The residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added. The reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C. The product was filtered and washed with methanol and dried to obtain 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]- 2-n-butyl benzofuran dioxalate salt. Purity > 98% (HPLC)
The dioxalate salt is characterized by XRD substantially as depicted in FIG.17 and DSC substantially as depicted in FIG.18
(B) 5-amino 3-[4-(3-di-n-burylamino-propoxy)benzoyll-2-n-butyl benzofuran
100 g 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt, 80 g of potassium carbonate, 500 mL toluene and 1 L of process water were stirred for 1 hour at 35°C. The reaction mixture was allowed at 50°C. The
separated aqueous layer was extracted with 100 mL toluene at 50°C. The separated combined organic layer was washed with water and stirred for 30 min. The separated organic layer was distilled under vacuum to obtain 85% 5-amino 3-[4-(3-di-n- butylamino-propoxy)benzoyl]-2-n-butyl benzofuran. Purity > 99.9% (HPLC)
Method-2:
(A) 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyll-2-n-butyl benzofuran dioxalate salt
100 g 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5-nitro benzofuran, 700 mL (30%) methanolic ammonia and 25 g of Pd/C (10%) were taken under nitrogen atmosphere at 25°C in 2.0 L autoclave. Hydrogen pressure of 0.5-1.0 Kg was flushed two times and released at 25°C. The hydrogen pressure upto 3.0 Kg/cm2 was applied and the reaction mixture was heated to 55°C. Further the pressure was increased to 5.0 Kg/cm2 and maintained for 8 hours at 55°C. After the completion of the reaction as monitored by TLC, the reaction mixture was cooled to 25°C. The reaction mixture was flushed with nitrogen pressure two times and filtered under nitrogen atmosphere at 25°C followed by washing with 50 mL methanol. The filtrate was distilled under vacuum at 65°C to obtain residue. The residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added. The reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C. The product was filtered and washed with methanol and dried to obtain 5-amino 3-[4-(3-di-n- butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt.
The dioxalate salt is characterized by XRD substantially as depicted in FIG.17 and DSC substantially as depicted in FIG.18
The process can also be conveniently completed by using dry methanolic ammonia solution prepared by using ammonia gas in methanol.
The dioxalate salt can be converted to free base as per the process described in method- 1.
Method-3:
(A) 5-amino 3-f4-(3-di-n-butylamino-propoxy)benzoyll-2-n-butyl benzofuran dioxalate salt
100 g 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5-nitro benzofuran, 700 mL mixture of methanol and ethyl acetate (30%) and 25 g of Pd/C (10%) were taken under nitrogen atmosphere at 25°C in 2.0 L autoclave. Hydrogen pressure of 0.5-
1.0 Kg was flushed two times and released at 25°C. The hydrogen pressure upto 3.0 Kg/cm2 was applied and the reaction mixture was heated to 55°C. Further the pressure was increased to 5.0 Kg/cm2 and maintained for 8 hours at 55°C. After the completion of the reaction as monitored by TLC, the reaction mixture was cooled to 25°C. The reaction mixture was flushed with nitrogen pressure two times and filtered under nitrogen atmosphere at 25°C followed by washing with 50 mL methanol. The filtrate was distilled under vacuum at 65°C to obtain residue. The residue was dissolved in methanol at 25°C and 52.20 g oxalic acid solution in methanol was added. The reaction mixture was heated to 65°C and stirred for 30 min at 50°C followed by cooling to 25°C. The product was filtered and washed with methanol and dried to obtain 5-amino 3-[4- (3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate salt. Purity > 98% (HPLC). The dioxalate salt is characterized by XRD substantially as depicted in FIG.17 and DSC substantially as depicted in FIG.18
The dioxalate salt can be converted to freebase as per the process described in method- 1.
Exam Ie-5:
Preparation of 2-n-butyl3-i4-(3-di-n-buty amino-propoxy)benzoyll5-methyIsulfon- amido benzofuran (Dronedarone)
100 g of 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran and 1 L toluene are heated to 105°C for 30 min. 100 mL solution of methane sulfonyl chloride in toluene was added within 30 min at 108°C and stirred for 3 hours. After the completion of the reaction as monitored by TLC, the reaction mixture was cooled to 25°C. The reaction mixture was quenched with 5% sodium bicarbonate solution 400 mL and heated to 60°C for 30 min. The organic layer was separated and washed with 250 mL of water at 60°C. The separated organic layer was charcoalized with 2.5 g activated charcoal at 60°C and filtered through hyflow bed and washed with 100 mL toluene at 60°C. The organic layer was distilled under vacuum to obtain 95% 2-n-butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]5-methyl-sulfonamido benzofuran (dronedarone) as an oil. Purity > 99.5% (HPLC).
Example-6:
Preparation of Dronedarone Hydrochloride
100 g dronedarone free base as oil and 175 mL ethyl acetate was taken in round bottom flask at 25°C and stirred for 15 min. 2.5 g activated carbon was added and
stirred for 30 min. The reaction mixture was filtered through hyflow bed and washed with 100 mL ethyl acetate. The organic layer was cooled to 0°C and 52.50 g isopronolic hydrochloride solution was added at 0°C. The reaction mixture was stirred at 0°C and heated to 70°C for 30 min. The reaction mixture was gradually cooled to 0°C and stirred for 1 hour. The precipitated product was filtered and washed with 100 mL chilled ethyl acetate and further dried to obtain dronedarone hydrochloride.
Exam le-7:
Preparation of Dronedarone Hydrochloride
100 g dronedarone free base as oil and 175 mL isopropanol was taken in round bottom flask at 25°C and stirred for 15 min. 2.5 g activated carbon was added and stirred for 30 min. The reaction mixture was filtered through hyflow bed and washed with 100 mL isopropanol. The organic layer was cooled to 0°C and 52.50 g isopronolic hydrochloride solution was added at 0°C. The reaction mixture was stirred at 0°C and heated to 70°C for 30 min. The reaction mixture was gradually cooled to 0°C and stirred for 1 hour. The precipitated product was filtered and washed with 100 mL chilled isopropanol and further dried to obtain dronedarone hydrochloride.
Example-8:
Preparation of Dronedarone Hydrochloride
100 g dronedarone freebase as oil and 175 mL acetone was taken in round bottom flask at 25°C and stirred for 15 min. 2.5 g activated carbon was added and stirred for 30 min. The reaction mixture was filtered through hyflow bed and washed with 100 mL acetone. The organic layer was cooled to 0°C and 52.50 g isopronolic hydrochloride solution was added at 0°C. The reaction mixture was stirred at 0°C and heated to 70°C for 30 min. The reaction mixture was gradually cooled to 0°C and stirred for 1 hour. The precipitated product was filtered and washed with 100 mL chilled acetone and further dried to obtain dronedarone hydrochloride.
Example-9:
Preparation of Dronedarone Hydrochloride
100 g dronedarone freebase as oil and 175 mL acetone was taken in round bottom flask at 25°C and stirred for 15 min. 2.5 g activated carbon was added and stirred for 30 min. The reaction mixture was filtered through hyflow bed and washed with 100 mL acetone. The organic layer was cooled to 0°C and 52.50 g isopronolic hydrochloride solution was added at 0°C. The reaction mixture was stirred at 0°C and
heated to 70°C for 30 min. The reaction mixture was gradually cooled to 0°C and stirred for 1 hour. The precipitated product was filtered and washed with 100 mL chilled acetone and further dried to obtain dronedarone hydrochloride.
Example-10:
Preparation of Dronedarone Hydrochloride Form A
100 g dronedarone hydrochloride and 400 mL acetone were taken in round bottom flask at and heated at 60°C for 30 min. The reaction mixture was cooled to 0°C and stirred for 1 hour to precipitate crystalline dronedarone hydrochloride. The product was filtered and washed with chilled 200 mL chilled acetone and further dried in hot air oven for about 8 hours at 60°C to 65°C to obtain crystalline dronedarone hydrochloride Form-A in 80% yield. The crystalline Form A is characterized by XRD substantially as depicted in FIG.l, Infrared spectrum substantially as depicted in FIG.2 and DSC substantially as depicted in FIG.3.
Example-11:
Preparation of Amorphous dronedarone hydrochloride
25.0 g of crystalline dronedarone hydrochloride is dissolved in 250.0 mL of acetone at 25°C to 30°C. The content is stirred for 30 minutes at 25°C to 30°C. To this, 1.0 g charcoal was added and stirred for 30 minutes at 25°C to 30°C. The content is filtered through Hyflosupercel, and the Hyflosupercel pad is washed with 50.0 mL acetone. The filtrate is concentrated under vacuum below 45°C till 100 mL acetone remains. 50 mL acetone was added and stirred to get clear solution. The reaction mixture followed by spray drying in JISL Mini spray drier LSD-48 under the below conditions. The product is collected from cyclone and is further dried at 40°C±5°C under vacuum for 16 hours to get 19.0 g of stable amorphous dronedarone hydrochloride.
The spray-dried Dronedarone hydrochloride is amorphous in nature. The obtained product contains residual solvent well within ICH limit.
Example-12:
Preparation of crystalline dronedarone hvdrobromide
15 g dronedarone freebase as solid and 30 mL ethyl acetate was taken in round bottom flask at 25°C and heated to 65°C for 1 hour. 7.4 g of cone. Hydrobromic acid (48%) solution was added and stirred for 30 min. 90 mL hexane was added to the reaction mixture and cooled to 25°C.The reaction mixture was stirred for 30 mins and filtered. The wet-cake was washed with hexane and dried to obtain 15 g (87%) of crystalline dronedarone hydrobromide. The crystalline form is characterized by XRD substantially as depicted in FIG.4, Infrared spectrum substantially as depicted in FIG.5 and DSC substantially as depicted in FIG.6.
Example-13:
Preparation of Amorphous dronedarone hvdrobromide
10.0 g of crystalline dronedarone hydrobromide is dissolved in 250.0 mL of acetone at 25°C to 30°C. The content is stirred for 30 minutes at 25°C to 30°C. To this, 1.0 g charcoal was added and stirred for 30 minutes at 25°C to 30°C. The content is filtered through Hyflosupercel, and the Hyflosupercel pad is washed with 50.0 mL acetone. The filtrate is concentrated under vacuum below 45°C till 100 mL acetone remains. 50 mL acetone was added and stirred to get clear solution. The solution was spray dried in JISL Mini spray drier LSD-48 under the below conditions. The product is collected from cyclone and is further dried at 40°C ± 5°C under vacuum for 16 hours to get 7.5.0 g of amorphous dronedarone hydrobromide.
The spray-dried dronedarone hydrobromide is amorphous in nature. The obtained product contains residual solvent well within ICH limit. The amorphous form is characterized by XRD substantially as depicted in FIG.7.
Example-14:
Preparation of crystalline dronedarone hydrogensulfate
10 g dronedarone freebase as solid and 50 mL ethyl acetate was taken in round bottom flask at 25°C and stirred to get clear solution. Cone. Sulfuric acid solution (1 gm in 10 ml ethyl acetate) was added and stirred for 30 min. The reaction mixture was heated to 65°C to 70°C and stirred for 30 tnins. The reaction mixture was cooled to 25°C and filtered. The wet-cake was washed with ethyl acetate and dried to obtain 9.6 g (75%) of crystalline dronedarone hydrogensulfate. The crystalline form is characterized by XRD substantially as depicted in FIG.8, Infrared spectrum substantially as depicted in FIG.9 and DSC substantially as depicted in FIG.10.
Example-15:
Preparation of Amorphous dronedarone hydrogensulfate
10.0 g of crystalline dronedarone hydrogensulfate is dissolved in 250.0 mL of ethyl acetate at 25°C to 30°C. The content is stirred for 30 minutes at 25°C to 30°C. To this, 1.0 g charcoal was added and stirred for 30 minutes at 25°C to 30°C. The content is filtered through Hyflosupercel, and the Hyflosupercel pad is washed with 50.0 mL ethyl acetate. The filtrate is concentrated under vacuum below 45°C till 100 mL acetone remains. 50 mL ethyl acetate was added and stirred to get clear solution. The solution was spray dried in JISL Mini spray drier LSD-48 under the below conditions. The product is collected from cyclone and is further dried at 40°C±5°C under vacuum for 16 hours to get 7.5 g of amorphous dronedarone hydrogensulfate.
,The spray-dried Dronedarone hydrobromide is amorphous in nature. The obtained product contains residual solvent well within ICH limit. The amorphous form is characterized by XRD substantially as depicted in FIG. l 1.
Example-16:
Preparation of crystalline dronedarone free base
185 g dronedarone hydrochloride Form-A and 925 mL toluene was taken in round bottom flask at 25°C and stirred for 15 minutes. 52 g potassium carbonate aqueous solution was added to the reaction mixture and stirred for 30 mins. The aqueous layer was separated and extracted with 185 mL toluene. The combined toluene layer was washed with water and distilled under vacuum to remove toluene. The residue was treated with 925 mL hexane and cooled to 0°C. The reaction mixture was cooled overnight and precipitated solid was filtered and washed with chilled hexane. The product was dried to obtain 145 g of dronedarone free base solid. The crystalline form is characterized by XRD substantially as depicted in FIG.12, Infrared spectrum substantially as depicted in FIG.13 and DSC substantially as depicted in FIG.14.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
/
Claims
1. A process for the preparation of dronedarone of Formula (I) or its hydrochloride
with l -chloro-3-di-n-butylamino propane in one or more suitable solvents in the presence of a suitable base to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)- benzoyl]-5-nitro benzofuran of Formula (IV);
(IV)
(b) optionally, isolating 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzo- furan acid addition salt of Formula (IVA) by reacting with one or more suitable acids and liberating compound of Formula (IV) by treating with a suitable base;
. Acid Addition Salt
(IVA)
(c) hydrogenating the compound of Formula (IV) in the presence of Raney Nickel, Palladium catalyst, Platinum oxide, Fe-HCl, Sn-HCl, or Na2Sx to obtain 5-amino 3- [4-(3-di-n-butylamin -propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III);
(ΠΙ)
(d) optionally, preparing 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (ΠΙΑ) by reacting with one or more suitable acids and obtaining the compound of Formula (III) by treating with a suitable base;
. Acid Addition Salt
(ΙΠΑ)
(e) , reacting the compound of Formula (III) with methanesulfonyl chloride or methanesulfonic anhydride in the absence of a base in one or more suitable solvents to obtain dronedarone; and
(f) optionally, converting the dronedarone to its hydrochloride salt by treating with a hydrochloric acid source. ~
2. The process as claimed in claim 1, wherein the suitable solvent at step 1(a) comprises one or more of acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, propanol, isobutanol, ethyl acetate, n-butyl acetate, tert-butyl acetate, propyl acetate, toluene, xylene, cyclohexane, n-heptane, acetonitrile, and the like.
3. The process as claimed in claim 1, wherein the suitable base comprises one or more of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide triethylamine, diisopropylamine, n-butylamine, diisopropylethylamine, pyridine, piperidine, ammonia, and the like.
4. The process as claimed in claim 1, wherein the suitable acid comprises one or more of hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric
acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid and camphoric acid, or a hydrate thereof.
5. The process as claimed in claim 1 , wherein the hydrochloride source comprises one or more of dry HC1 (g), isopropanolic HC1, aqueous HC1, cone. HC1, ethyl acetate- HC1, and the like.
6. A process for the preparation of 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V),
(V)
the process comprising:
(a) reacting 2-n-butyl-5-nitrobenzofuran with anisoyl chloride in the presence of a lewis acid in one or more solvents to obtain 2-n-Butyl-3-(4-methoxybenzoyl)-5- nitrobenzofuran of Formula (VI), with a proviso that lewis acid is not tin tetrachloride and haloge loroethane;
(b) demethylating the 2-n-butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran of Formula (VI) in the presence of a lewis acid catalyst in one or more suitable solvents;
(c) extracting in one or more suitable solvents and removing the solvent to get a residue;
(d) treating the residue with one or more suitable solvents; and
(e) isolating the 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V).
7. The process as claimed in claim 6, wherein the solvent at step 6(a) comprises one or more of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, heptanes, and the like.
8. The process as claimed in claim 6, wherein the lewis acid comprises one or more of aluminum chloride, zinc chloride, boron trifluoride, stannic chloride, titanium tetrachloride, and ferric chloride.
9. The process as claimed in claim 6, wherein the suitable solvent at step 6(b) comprises one or more of CMO alcohols, C3-8 ketones, C esters, halogenated and non-halogenated hydrocarbons, amides, nitriles, and the like.
10. The process as claimed in claim 9, wherein the suitable solvent comprises methanol, ethanol, isopropanol, butanol, pentanol, dodecanol, acetone, methyl isobutyl ketone, methyl ethyl ketone, ethyl acetate, tert-butyl acetate, n-butyl acetate, methylene dichloride, chlorobenzene, toluene, xylene, N,N- dimethylformamide, Ν,Ν-dimethyl- acetamide, acetonitrile, N-methylpyrrolidone, N,N-dimethylsulfoxide, sulfolane, and the like.
11. The process as claimed in claim 6, wherein the suitable solvents at steps 6(c) or (d), comprise one or more of methylene dichloride, chlorobenzene, toluene, xylene, cyclohexane, n-heptane, n-hexane, ethyl acetate, butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, and the like.
12. A process for the preparation of 5-amino 3-[4-(3-di-n-butylamino- propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA),
. Acid Addition Salt
(IIIA)
the process comprising:
(a) reacting 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran of Formula (V) with 1- chloro-3-di-n-butylamino propane in one or more suitable solvents in the presence of a suitable base to obtain 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5- nitro benzofuran of For
(b) optionally, isolating 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzo- furan acid addition salt of Formula (IVA) by reacting with one or more suitable acids and liberating the compound of Formula (IV) by treating with a suitable base;
. Acid Addition Salt
(IVA)
(c) hydrogenating the compound of Formula (IV) with Raney Nickel or 10% Palladium on carbon to obtain 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III); and
(III)
(d) isolating the 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran acid addition salt of Formula (IIIA) by reacting with one or more suitable acids.
13. The process as claimed in claim 12, wherein the acid addition salts comprise one or more of hydrobromide, hydrochloride, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate, and the like.
14. A process for the preparation of dronedarone of Formula (I) or its hydrochloride salt;
(I)
the process comprising:
(a) reacting 5-amino 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran of Formula (III),
with methane sulfonyl chloride or methane sulfonic anhydride in the absence of a base in one or more suitable solvents to obtain dronedarone of Formula (I);
(b) optionally, converting the dronedarone into one or more of its pharmaceutically acceptable acid addition salts and obtaining the dronedarone by treating with a suitable base; and
(c) converting the dronedarone to its hydrochloride salt by treating with a hydrochloric acid source.
15. The process as claimed in claim 14, wherein the suitable solvent comprises one or more of methanol, ethanol, isopropanol, butanol, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone and water.
16. The process as claimed in claim 14, wherein the pharmaceutically acceptable salts comprise salts with hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, benzenesulphonic acid, camphoric acid, and the like.
17. The process as claimed in claim 14, wherein the suitable base comprises one or more of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium hydride, sodium methoxide, sodium ethoxide, potassium tert-butoxide, and the like.
18. The process as claimed in claim 14, wherein the hydrochloride source comprises one or more of dry HC1 (g), isopropanolic HC1, aqueous HC1, cone. HC1, ethyl acetate-HCl, and the like.
19. A process for the preparation of dronedarone hydrochloride, the process comprising:
(a) combining dronedarone and one or more of suitable solvents comprising one or more of water, a hydrocarbon, C1 -4- ester, C2-4 ether, Ci-8 alcohol, acetonitrile, ketone, and the like;
(b) adding hydrochloric acid in an amount sufficient to form dronedarone hydrochloride; and
(c) isolating dronedarone hydrochloride.
20. The process as claimed in claim 19, wherein the suitable solvent comprises one or more of water, toluene, xylene, ethylbenzene, chlorobenzene, ethyl acetate, isopropyl acetate, n-butyl acetate, tert-butyl acetate, diethyl ether, diisopropyl ether, methyl tert-butyl ether, methanol, ethanol, isopropanol, butanol, dodecanol, acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone, or mixtures thereof.
21. Dronedarone or its pharmaceutically acceptable acid addition salts substantially free from disulfonamide impurity.
22. Dronedarone hydrochloride substantially free from disulfonamide impurity.
23. Crystalline 5-amino-3-[4-(3-di-n-butylamino-propoxy)benzoyl]-2-n-butyl benzofuran dioxalate Form-I characterized by X-ray powder diffraction having peaks at about 7.5, 10.0, 10.7, 15.3, 17.6, 20.1, 22.5, 24.6, 27.9 and 30.1±0.2° 2Θ or differential scanning calorimetry having endothermic peak at about 173.76°C.
24. Crystalline 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy)-benzoyl]-5-nitro benzofuran oxalate Form-I characterized by X-ray powder diffraction having peaks at about 5.6, 6.9, 7.3, 13.1, 18.0, 20.5, 23.3, 24.4 and 25.7±0.2° 20 or differential scanning calorimetry having endothermic peaks at about 87.85°C and 109.91 °C.
25. An isolated N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)- N-(methylsulfonyl)methane sulfonamide "disulfonamide impurity" of the following structure. ·
26. A process for the preparation of dronedarone hydrochloride having less than about 1% of N-(2-butyl-3 (4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)methane sulfonamide (disulfonamide impurity) determined by HPLC; comprising: measuring level of the disulfonamide impurity in a batch of dronedarone free base, selected a batch having less than about 1% of disulfonamide impurity; converting dronedarone of the said batch to dronedarone hydrochloride by treating with an hydrochloric acid source.
27. A pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride substantially free from disulfonamide impurity.
28. A pharmaceutical composition comprising crystalline Form-A of dronedarone hydrochloride and one or more pharmaceutically acceptable carriers, excipients or diluents.
29. Pharmaceutically acceptable acid addition salts of dronedarone selected from one or more of hydrobromide, hydrogensulfate, phosphate, oxalate, tartrate, succinate, maleate, fumarate, besylate, mesylate, tosylate, and the like.
30. The pharmaceutically acceptable acid addition salts as claimed in claim 29 having particle size distributions the 10th volume percentile particle size (Dio) is less than about 50 μηι, the 50th volume percentile particle size (Ds0) is less than about 250 μηι, or the 90th volume percentile particle size (D90) is less than about 500 μπι, or any combination thereof.
31. The pharmaceutically acceptable acid addition salts as claimed in claim 29, which are crystalline.
32. The pharmaceutically acceptable acid addition salts as claimed in claim 29, which are amorphous.
33. Crystalline dronedarone hydrobromide characterized by at least one of the following:
(a) X-ray powder diffraction having characteristic peaks at about 7.6°, 8.0°, 13.0, 13.5, 15.4, 16.1, 20.1 , 20.6, 22.2, 22.9, 23.7 and 25.8±0.2° (2Θ) or X-ray powder diffraction substantially as depicted in FIG.4; or
(b) IR spectra having characteristic peaks at 3984, 2872, 2686, 2600, 1638, 1602, 1572, 1257, 1 157, 1048, 975, 777, 656, and 509 crn 1 or Fourier Transfer Infrared spectra substantially as depicted in FIG.5; or
(c) DSC having endothermic peak at about 134.97°C or differential scanning calorimetry substantially as depicted in FIG.6.
32. Crystalline dronedarone hydrogensulfate characterized by at least one of the following:
(a) X-ray powder diffraction having characteristic peaks at about 4.7°, 10.1°, 18.0°, 20.0°, 22.0°, 23.6° and 25.5°±0.2° (2Θ) or X-ray powder diffraction substantially as depicted in FIG.8; or
• (b) IR spectra having characteristic peaks at 2960, 2933, 2872, 1735, 161 1, 1598, 1571, 1508, 1465, 1371, 1253, 1 157, 1 1 16, 1020, 929, 904 815, 777, and 522 cm"1 or Fourier Transfer Infrared spectra substantially as depicted in FIG.9; or
(c) DSC having endothermic peak at about 114.97°C or differential scanning calorimetry substantially as depicted in FIG.10.
34. Crystalline Form-A of dronedarone hydrochloride characterized by at least one of the following:
(a) X-ray powder diffraction having peaks at about 7.6, 8.0, 1 1.8, 13.7, 15.6, 19.9, 21.5, 23.4, 23.8, 26.0 and 26.8±0.2° 2Θ or X-ray powder diffraction substantially as depicted in FIG.1 ; or
(b) Fourier Transform Infrared spectra having peaks at about 3060, 2872, 2488, 1637, 1602, 1570, 1462, 1373, 1255, 1 155, 977, 810, 777, 667 and 505 cm"1 or Fourier Transfer Infrared spectra substantially as depicted in FIG.2; or
(c) Differential scanning calorimetry having endothermic peak at about 145.54°C or differential scanning calorimetry substantially as depicted in FIG.3.
35. Amorphous dronedarone hydrobromide characterized by X-ray powder diffraction substantially as depicted in FIG.7.
35. Amorphous dronedarone hydrogensulfate characterized by X-ray powder diffraction substantially as depicted in FIG. l 1.
36. Amorphous dronedarone hydrochloride characterized by X-ray powder diffraction substantially as depicted in FIG.19.
37. Crystalline Form-A of dronedarone hydrochloride having particle size distributions wherein the 10th volume percentile particle size (D10) is less than about 20 μηι, the 50th volume percentile particle size (D50) is less than about 50 μιη, or the 90th volume percentile particle size (D90) is less than about 100 μηι, or any combination thereof.
38. A process for the preparation of pharmaceutically acceptable acid addition salts of dronedarone, the process comprising:
(a) providing a solution of dronedarone in one or more suitable solvents;
(b) adding a suitable acid selected from hydrobromic acid, sulfuric acid, hydrochloric acid, phosphoric acid, oxalic acid, tartartic acid, succinic acid, maleic acid, fumaric acid, benzenesulfonic acid, methanesulfonic acid, toluenesulfonic acid; and
(c) isolating the pharmaceutically acceptable acid addition salts of dronedarone by removal of solvents.
39. The process as claimed in claim 38, wherein the suitable solvent comprises one or more of Q-C4 alcohols, ketones, esters, aprotic solvents, water, or mixtures thereof.
40. The process as claimed in claim 39, wherein the suitable solvent comprises one or more of methanol, ethanol, isopropanol, n-butanol, heptanol, decanol, dodecanol, acetone, methyl ethyl ketone, methyl tert-butyl ketone, ethyl acetate, isopropyl acetate, butyl acetate, n-propyl acetate, dimethyl formamide, dimethyl acetamide, N-methylpyrrolidone, acetonitrile and water, or mixtures thereof.
41. The process as claimed in claim 38, wherein removing the solvent comprises one or more of filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum.
42. The process as claimed in claim 38, wherein the process optionally includes addition of one or more of a suitable anti-solvent.
43. A process for the preparation of amorphous form of pharmaceutically acceptable acid addition salts of dronedarone, the process comprising:
(a) providing a solution of pharmaceutically acceptable acid addition salts of dronedarone in one or more suitable solvents; and
(b) isolating the amorphous form of pharmaceutically acceptable acid addition salts of dronedarone.
44. The process as claimed in claim 43, wherein the isolation comprises using one or more of suitable techniques comprising rotational distillation, spray drying, agitated thin film drying, and freeze drying.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2481/MUM/2010 | 2010-09-08 | ||
IN2481MU2010 | 2010-09-08 | ||
IN1519/MUM/2011 | 2011-05-18 | ||
IN1519MU2011 | 2011-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012032545A1 true WO2012032545A1 (en) | 2012-03-15 |
Family
ID=45464037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2011/000614 WO2012032545A1 (en) | 2010-09-08 | 2011-09-08 | Processes for preparing dronedarone and its intermediates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012032545A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102690250A (en) * | 2012-05-08 | 2012-09-26 | 郑州明泽医药科技有限公司 | Dronedarone intermediate and preparation method thereof |
WO2012131408A1 (en) * | 2011-03-29 | 2012-10-04 | Sanofi | Process for preparation of dronedarone by mesylation |
CN102725279A (en) * | 2010-11-08 | 2012-10-10 | 山东邹平大展新材料有限公司 | Method for preparing dronedarone hydrochloride |
WO2012120544A3 (en) * | 2011-03-10 | 2012-11-01 | Sun Pharmaceutical Industries Ltd. | Process for the preparation of n- [2-n-butyl-3-[4-[3-[di-n-butylamino] propoxy] benzoyl] benzofuran-5-yl]methanesul fonamide hydrochloride |
CN103694206A (en) * | 2013-12-05 | 2014-04-02 | 福建广生堂药业股份有限公司 | Novel dronedarone hydrochloride crystal form and preparation method thereof |
CN104892553A (en) * | 2015-04-27 | 2015-09-09 | 惠州信立泰药业有限公司 | Dronedarone hydrochloride crystal and preparation method thereof and pharmaceutical composition containing dronedarone hydrochloride crystal |
US9174959B2 (en) | 2011-03-29 | 2015-11-03 | Sanofi | Process for preparation of dronedarone by N-butylation |
US9174958B2 (en) | 2010-06-18 | 2015-11-03 | Sanofi | Process for the preparation of dronedarone |
US9221778B2 (en) | 2012-02-13 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9221777B2 (en) | 2012-01-20 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9238636B2 (en) | 2012-05-31 | 2016-01-19 | Sanofi | Process for preparation of dronedarone by Grignard reaction |
US9249119B2 (en) | 2012-02-14 | 2016-02-02 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
US9334254B2 (en) | 2010-03-30 | 2016-05-10 | Sanofi | Process for preparing sulfonamidobenzofuran derivatives |
US9382223B2 (en) | 2012-02-22 | 2016-07-05 | Sanofi | Process for preparation of dronedarone by oxidation of a hydroxyl group |
US9499507B2 (en) | 2011-11-29 | 2016-11-22 | Sanofi | Method for preparing 5-amino-benzoyl-benzofuran derivatives |
US10576056B2 (en) | 2015-12-24 | 2020-03-03 | Mcmaster University | Compounds for treating cancer and methods of use thereof |
CN112442003A (en) * | 2020-12-17 | 2021-03-05 | 南京方生和医药科技有限公司 | Dronedarone intermediate impurity and preparation method thereof |
US11872207B2 (en) | 2015-12-24 | 2024-01-16 | Mcmaster University | Dronedarone and derivatives thereof for treating cancer |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223510A (en) | 1990-08-06 | 1993-06-29 | Sanofi | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
WO2001029019A1 (en) | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Method for preparing a benzofuran or benzothiophene compound |
WO2001028974A2 (en) | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Intermediates for making a benzofuran or benzothiophene derivative nitrated in position 5 and uses thereof |
US20040010032A1 (en) * | 2000-12-11 | 2004-01-15 | Michel Biard | 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof |
US20040048921A1 (en) * | 2000-12-11 | 2004-03-11 | Noel Fino | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate |
US20050049302A1 (en) * | 2001-11-08 | 2005-03-03 | Arie Gutman | Process for the preparation of dronedarone |
US6984741B2 (en) | 2002-08-19 | 2006-01-10 | Bayer Aktiengesellschaft | 5-Nitrobenzofurans |
WO2010040261A1 (en) | 2008-10-10 | 2010-04-15 | Lonza Ltd | Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans |
US20110009649A1 (en) | 2007-04-06 | 2011-01-13 | Finorga | METHOD FOR PREPARING 2-(n-BUTYL)-5-NITROBENZOFURAN |
CN102070577A (en) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-n-butyl-3-(4-subsitituted propylbenzoyl)-5-substituted amino benzofuran and application thereof |
CN102070581A (en) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | Preparation of 2-n-butyl-3-(4-(3-di-n-butylaminopropyl) benzoyl)-5-amino benzofuran |
WO2011070380A1 (en) | 2009-12-08 | 2011-06-16 | Sanofi-Aventis | New process for the preparation of dronedarone |
EP2354132A2 (en) | 2010-02-05 | 2011-08-10 | Sanofi | Crystallized form of dronedarone base |
CN102180848A (en) * | 2010-12-31 | 2011-09-14 | 江苏万全特创医药生物技术有限公司 | Preparation method for novel antiarrhythmic medicament of dronedarone |
EP2371824A1 (en) * | 2010-03-08 | 2011-10-05 | Ratiopharm GmbH | Crystalline dronedarone salts |
WO2012004658A2 (en) * | 2010-07-09 | 2012-01-12 | Frichem Private Limited | Process for preparation of n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide, acid addition salts and product thereof |
-
2011
- 2011-09-08 WO PCT/IN2011/000614 patent/WO2012032545A1/en active Application Filing
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223510A (en) | 1990-08-06 | 1993-06-29 | Sanofi | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
WO2001029019A1 (en) | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Method for preparing a benzofuran or benzothiophene compound |
WO2001028974A2 (en) | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Intermediates for making a benzofuran or benzothiophene derivative nitrated in position 5 and uses thereof |
US6855842B1 (en) | 1999-10-21 | 2005-02-15 | Rhodia Chimie | Intermediates for making a bezofuran or benzothiophene derivative nitrated in position 5 and uses thereof |
US20040010032A1 (en) * | 2000-12-11 | 2004-01-15 | Michel Biard | 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof |
US20040048921A1 (en) * | 2000-12-11 | 2004-03-11 | Noel Fino | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate |
US6828448B2 (en) | 2000-12-11 | 2004-12-07 | Sanofi-Synthelabo | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate |
US6846936B2 (en) | 2000-12-11 | 2005-01-25 | Sanofi-Synthelabo | 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof |
US7312345B2 (en) | 2001-11-08 | 2007-12-25 | Isp Investments Inc. | Process for the preparation of dronedarone |
US20050049302A1 (en) * | 2001-11-08 | 2005-03-03 | Arie Gutman | Process for the preparation of dronedarone |
US6984741B2 (en) | 2002-08-19 | 2006-01-10 | Bayer Aktiengesellschaft | 5-Nitrobenzofurans |
US20110009649A1 (en) | 2007-04-06 | 2011-01-13 | Finorga | METHOD FOR PREPARING 2-(n-BUTYL)-5-NITROBENZOFURAN |
WO2010040261A1 (en) | 2008-10-10 | 2010-04-15 | Lonza Ltd | Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans |
WO2011070380A1 (en) | 2009-12-08 | 2011-06-16 | Sanofi-Aventis | New process for the preparation of dronedarone |
EP2354132A2 (en) | 2010-02-05 | 2011-08-10 | Sanofi | Crystallized form of dronedarone base |
EP2371824A1 (en) * | 2010-03-08 | 2011-10-05 | Ratiopharm GmbH | Crystalline dronedarone salts |
WO2012004658A2 (en) * | 2010-07-09 | 2012-01-12 | Frichem Private Limited | Process for preparation of n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide, acid addition salts and product thereof |
CN102180848A (en) * | 2010-12-31 | 2011-09-14 | 江苏万全特创医药生物技术有限公司 | Preparation method for novel antiarrhythmic medicament of dronedarone |
CN102070577A (en) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-n-butyl-3-(4-subsitituted propylbenzoyl)-5-substituted amino benzofuran and application thereof |
CN102070581A (en) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | Preparation of 2-n-butyl-3-(4-(3-di-n-butylaminopropyl) benzoyl)-5-amino benzofuran |
Non-Patent Citations (4)
Title |
---|
G. M. WALL, PHARM MANUF., vol. 3, 1986, pages 33 |
H. R. HORTON; D. E. KOSHLAND, J. METHODS IN ENZYMOLOGY, vol. 11, 1967, pages 556 |
J. K. HALEBLIAN, J. PHARM. SCI., vol. 64, 1975, pages 1269 |
J. K. HALEBLIAN; W. MCCRONE, J. PHARM. SCI., vol. 58, 1969, pages 911 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9334254B2 (en) | 2010-03-30 | 2016-05-10 | Sanofi | Process for preparing sulfonamidobenzofuran derivatives |
US9174958B2 (en) | 2010-06-18 | 2015-11-03 | Sanofi | Process for the preparation of dronedarone |
CN102725279A (en) * | 2010-11-08 | 2012-10-10 | 山东邹平大展新材料有限公司 | Method for preparing dronedarone hydrochloride |
WO2012120544A3 (en) * | 2011-03-10 | 2012-11-01 | Sun Pharmaceutical Industries Ltd. | Process for the preparation of n- [2-n-butyl-3-[4-[3-[di-n-butylamino] propoxy] benzoyl] benzofuran-5-yl]methanesul fonamide hydrochloride |
US9193703B2 (en) | 2011-03-29 | 2015-11-24 | Sanofi | Process for preparation of dronedarone by mesylation |
WO2012131408A1 (en) * | 2011-03-29 | 2012-10-04 | Sanofi | Process for preparation of dronedarone by mesylation |
US9611242B2 (en) | 2011-03-29 | 2017-04-04 | Sanofi | Process for preparation of dronedarone by N-butylation |
US9174959B2 (en) | 2011-03-29 | 2015-11-03 | Sanofi | Process for preparation of dronedarone by N-butylation |
US9499507B2 (en) | 2011-11-29 | 2016-11-22 | Sanofi | Method for preparing 5-amino-benzoyl-benzofuran derivatives |
US9708281B2 (en) | 2012-01-20 | 2017-07-18 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9221777B2 (en) | 2012-01-20 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9221778B2 (en) | 2012-02-13 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9701654B2 (en) | 2012-02-13 | 2017-07-11 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9249119B2 (en) | 2012-02-14 | 2016-02-02 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
US9382223B2 (en) | 2012-02-22 | 2016-07-05 | Sanofi | Process for preparation of dronedarone by oxidation of a hydroxyl group |
CN102690250A (en) * | 2012-05-08 | 2012-09-26 | 郑州明泽医药科技有限公司 | Dronedarone intermediate and preparation method thereof |
US9238636B2 (en) | 2012-05-31 | 2016-01-19 | Sanofi | Process for preparation of dronedarone by Grignard reaction |
CN103694206B (en) * | 2013-12-05 | 2015-09-16 | 福建广生堂药业股份有限公司 | A kind of Novel dronedarone hydrochloride crystal form and preparation method thereof |
CN103694206A (en) * | 2013-12-05 | 2014-04-02 | 福建广生堂药业股份有限公司 | Novel dronedarone hydrochloride crystal form and preparation method thereof |
CN104892553B (en) * | 2015-04-27 | 2017-06-20 | 惠州信立泰药业有限公司 | A kind of crystal of dronedarone hydrochloride and preparation method thereof and the pharmaceutical composition containing the crystal |
CN104892553A (en) * | 2015-04-27 | 2015-09-09 | 惠州信立泰药业有限公司 | Dronedarone hydrochloride crystal and preparation method thereof and pharmaceutical composition containing dronedarone hydrochloride crystal |
US10576056B2 (en) | 2015-12-24 | 2020-03-03 | Mcmaster University | Compounds for treating cancer and methods of use thereof |
US11872207B2 (en) | 2015-12-24 | 2024-01-16 | Mcmaster University | Dronedarone and derivatives thereof for treating cancer |
CN112442003A (en) * | 2020-12-17 | 2021-03-05 | 南京方生和医药科技有限公司 | Dronedarone intermediate impurity and preparation method thereof |
CN112442003B (en) * | 2020-12-17 | 2022-04-19 | 南京方生和医药科技有限公司 | Dronedarone intermediate impurity and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012032545A1 (en) | Processes for preparing dronedarone and its intermediates | |
AU2002366383B2 (en) | Polymorphs of clopidogrel hydrogensulfate | |
CA2793312C (en) | Anhydrous lenalidomide form-i | |
US6767913B2 (en) | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms | |
KR102266680B1 (en) | Polymorphic Forms of Belinostet and Methods of Making It | |
DK2240431T3 (en) | CRYSTALLIC MODIFICATION OF (1R, 2R) -3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL | |
KR20120139763A (en) | Raltegravir salts and crystalline forms thereof | |
KR101391746B1 (en) | Indanone derivatives, pharmaceutically acceptable salts thereof or optical isomer thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of the viral diseases containing the same as an active ingredient | |
EP1720843A2 (en) | Process for the preparation of substituted triazole compounds | |
WO2011024192A2 (en) | Novel polymorphs of raltegravir | |
US20070203176A1 (en) | Crystalline forms of dolasetron base and processes for preparation thereof | |
US10377712B2 (en) | Process for preparation of apremilast and novel polymorphs thereof | |
JP2018035158A (en) | Novel forms of multicyclic compound | |
US7074928B2 (en) | Polymorphs of clopidogrel hydrogensulfate | |
WO2011121607A2 (en) | Rasagiline and its pharmaceutically acceptable salts | |
TWI761826B (en) | Salts of diaminopyrimidine compounds, solid forms thereof, and preparation methods and uses thereof | |
US20080262025A1 (en) | Processes for the Preparation of Zolpidem and its Hemitartrate | |
TWI773987B (en) | Solid form of diaminopyrimidine compound or its hydrate and its preparation method and use | |
KR101693901B1 (en) | Method for preparing a non-hydratable crystal form | |
WO2016172333A1 (en) | A solid state form of perampanel | |
JP2011505416A (en) | Process for the preparation of chemically and chirally pure solifenacin base and its salts | |
US11434226B2 (en) | Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof | |
WO2017167949A1 (en) | Crystalline forms of bilastine | |
WO2012153225A1 (en) | Improved processes for obtaining high purity of dronedarone hydrochloride | |
KR20200092945A (en) | Lenalidomide Crystalline Form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11805622 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11805622 Country of ref document: EP Kind code of ref document: A1 |